Protocol J3L-MC-EZEB Initial Protocol 
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and 
Safety of LY3819469 in Adults With Elevated Lipoprotein(a) 
[STUDY_ID_REMOVED]
Approval Date: 19-Jul-2022
CONFIDENTIAL  J3L-MC-EZEB  
1 Title  Page  
Confidential Information  
The information contained in this document is confidential and is intended for the use of clinical investigators. It is the p roperty of 
Eli Lilly and Company or its subsidiaries and should not be copi[INVESTIGATOR_51937]3819469 , unless such persons are bound by a confidentiality agreement with Eli Lilly and Company or its 
subsidiaries.  
Note to Regulatory Authorities:  This document may contain protected personal data and/or commercially confidenti al information 
exempt from public disclosure. Eli Lilly and Company requests consultation regarding release/redaction prior to any public re lease. 
In the [LOCATION_002], this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not b e reproduced or 
otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries . 
Protocol Title:  
A Phase 2, Randomized, Double -Blind, Placebo -Controlled Study to Investigate the Efficacy and 
Safety of LY3819469 in Adults w ith Elevated Lipoprotein(a)  
Protocol Number:  J3L-MC-EZEB  
Amendment Number: This is the initial protocol. 
Compound : LY3819469  
Brief  Title:  
Efficacy and safety of LY3819469 compared with placebo in adults with elevated Lp(a)  
Study Phase: 2 
Sponsor Name: [CONTACT_11028]: Indianapolis, Indiana, [LOCATION_003] [ZIP_CODE]  
Regulatory Agency Identifier Number(s)  
IND: 154938  
EU trial number: 2022 -501426 -38-00 
Document  ID: VV-CLIN -068490  
Approval Date:  Protocol Electronically  Signed and  Approved  by [CONTACT_141693].  
Approved on [ADDRESS_199233] Infor mation will be provided separately . 
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
3 Table of Contents  
1. Protocol Summary  ................................ ................................ ................................ .......... 6
1.1. Synopsis  ................................ ................................ ................................ ............................ 6
1.2. Schema  ................................ ................................ ................................ .............................. 9
1.3. Schedule of Activities (SoA)  ................................ ................................ .......................... 10
2. Introduction  ................................ ................................ ................................ ................... 18
2.1. Study Rationale  ................................ ................................ ................................ ............... 18
2.2. Background  ................................ ................................ ................................ ..................... 18
2.2.1. Introduction to Lp(a)  ................................ ................................ ................................ .......18
2.2.2. Elevated Levels of Lp(a) Are Associated with Increased Risk of 
Cardiovascular Disease  ................................ ................................ ................................ ...19
2.2.3. Available Treatments  ................................ ................................ ................................ ......20
2.2.4. Introduction to LY3819469  ................................ ................................ ............................ 20
2.3. Benefit/Risk Assessment  ................................ ................................ ................................ 20
2.3.1. Risk Assessment  ................................ ................................ ................................ ............. 20
2.3.2. Benefit Assessment  ................................ ................................ ................................ ......... 21
2.3.3. Overall Benefit Risk Conclusion  ................................ ................................ .................... 21
3. Objectives, Endpoints, and Estimands  ................................ ................................ .......22
4. Study Design  ................................ ................................ ................................ .................. 24
4.1. Overall Design  ................................ ................................ ................................ ................ 24
4.2. Scientific Rationale for Study Design  ................................ ................................ ............ 24
4.2.1. Participant Input into Design  ................................ ................................ .......................... 25
4.3. Justification for Dose  ................................ ................................ ................................ ......25
4.4. End of Study Definition  ................................ ................................ ................................ ..25
5. Study Population  ................................ ................................ ................................ ........... 26
5.1. Inclusion Criteria  ................................ ................................ ................................ ............ 26
5.2. Exclusion Criteria  ................................ ................................ ................................ ........... 27
5.3. Lifestyle Considerations  ................................ ................................ ................................ .28
5.3.1. Meals and Dietary Restrictions  ................................ ................................ ....................... 28
5.3.2. Blood Donation  ................................ ................................ ................................ ............... 29
5.4. Screen Failures  ................................ ................................ ................................ ................ 29
5.5. Criteria for Temporarily Delaying 
Enrollment/Randomization/Administration of Study Intervention 
of a Partic ipant  ................................ ................................ ................................ ................ 29
6. Study Intervention(s) and Concomitant Therapy  ................................ ..................... 30
6.1. Study Intervention(s) Administered ................................ ................................ ................ 30
6.2. Preparation, Handling, Storage, and Accountability  ................................ ...................... 31
6.3. Measures to Minimize Bias: Randomization and Blinding  ................................ ............ 31
6.4. Study Intervention Compliance  ................................ ................................ ...................... 32
6.5. Dose Modification  ................................ ................................ ................................ .......... 32
6.6. Continued Access to Study Intervention after the End of the 
Study  ................................ ................................ ................................ ............................... 32
6.7. Treatment of Overdose  ................................ ................................ ................................ ...32
6.8. Concomitant Therapy  ................................ ................................ ................................ .....32
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
4 7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal ................................ ................................ ........................ 34 
7.1. Discontinuation of Study Intervention  ................................ ................................ ............ 34 
7.1.1.  Liver Chemistry Stoppi[INVESTIGATOR_2121]  ................................ ................................ .................. 35 
7.1.2.  QTc Stoppi[INVESTIGATOR_2121]  ................................ ................................ ................................ .....36 
7.2. Participant Discontinuation/Withdrawal from the Study  ................................ ................ [ADDRESS_199234] 
Complaints  ................................ ................................ ................................ ...................... 42 
8.3.1.  Timing and Mechanism for Collecting Events  ................................ ............................... 43 
8.3.2.  Pregnancy  ................................ ................................ ................................ ........................ 45 
8.3.3.  Major Adverse Cardiovascular Events  ................................ ................................ ........... 46 
8.4. Pharmacokinetics  ................................ ................................ ................................ ............ 46 
8.5. Pharmacodynamics  ................................ ................................ ................................ ......... 47 
8.6. Genetics  ................................ ................................ ................................ .......................... 47 
8.7. Biomarkers  ................................ ................................ ................................ ...................... 47 
8.8. Immunogenicity Assessments ................................ ................................ ......................... 47 
8.9. Health Economics  ................................ ................................ ................................ ........... 47 
9. Statistical Considerations  ................................ ................................ ............................. 48 
9.1. Statistical Hypotheses  ................................ ................................ ................................ .....48 
9.1.1.  Multiplicity Adjustment  ................................ ................................ ................................ ..48 
9.2. Analyses Sets  ................................ ................................ ................................ .................. 48 
9.3. Statistical Analyses  ................................ ................................ ................................ ......... 48 
9.3.1.  General Considerations  ................................ ................................ ................................ ...48 
9.3.2.  Primary Endpoint(s)/Estimand(s) Analysis  ................................ ................................ ....48 
9.3.3.  Secondary Endpoint(s)/Estimand(s) Analysis  ................................ ................................ 49 
9.3.4.  Exploratory Endpoint(s) Analysis ................................ ................................ ................... 49 
9.3.5.  Safety Analyses  ................................ ................................ ................................ ............... 49 
9.3.6.  Pharmacokinetic and Pharmacodynamic Analyses  ................................ ........................ 50 
9.3.7.  Immunogenicity Assessments  ................................ ................................ ......................... 51 
9.3.8.  Subgroup Analyses  ................................ ................................ ................................ ......... 51 
9.4. Interim Analysis  ................................ ................................ ................................ .............. 51 
9.5. Sample Size Determination  ................................ ................................ ............................ 52 
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
5 10. Supporting Documentation and Operational Considerations  ................................ ..53 
10.1.  Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations  ................................ ................................ ................................ ................ 53 
10.1.1.  Regulatory and Ethical Considerations  ................................ ................................ ........... 53 
10.1.2.  Financial Disclosure ................................ ................................ ................................ ........ 54 
10.1.3.  Informed Consent Process  ................................ ................................ .............................. 54 
10.1.4.  Data Protection ................................ ................................ ................................ ................ 54 
10.1.5.  Committees Structure ................................ ................................ ................................ ......55 
10.1.6.  Dissemination of Clinical Study Data ................................ ................................ ............. 55 
10.1.7.  Data Quality Assurance  ................................ ................................ ................................ ..55 
10.1.8.  Source Documents  ................................ ................................ ................................ .......... 57 
10.1.9.  Study and Site S tart and Closure  ................................ ................................ .................... 57 
10.1.10.  Publication Policy  ................................ ................................ ................................ ........... 58 
10.1.11.  Investigator Information  ................................ ................................ ................................ .58 
10.1.12.  Sample Retention  ................................ ................................ ................................ ............ 58 
10.2.  Appendix 2: Clinical Laboratory Tests  ................................ ................................ ........... 59 
10.2.1.  Laboratory  Samples to be Obtained at the Time of a Systemic 
Hypersensitivity Event  ................................ ................................ ................................ ....62 
10.3.  Appendix 3: Adverse Events and Serious Adverse Events: 
Definitions and Procedures for Recording, Evaluating, Follow -
up, and Reporting  ................................ ................................ ................................ ............ [ADDRESS_199235] Complaints  ................................ ................................ ................... 66 
10.3.4.  Recording and Follow -Up of AE and/or SAE and Product 
Complaints  ................................ ................................ ................................ ...................... 66 
10.3.5.  Reporting of SAEs  ................................ ................................ ................................ .......... 68 
10.3.6.  Regulatory Reporting Requirements  ................................ ................................ ............... 69 
10.4.  Appendix 4: Contraceptive and Barrier Guidance  ................................ .......................... 70 
10.4.1.  Definitions ................................ ................................ ................................ ....................... 70 
10.4.2.  Contraception Guidance ................................ ................................ ................................ ..70 
10.5.  Appendix 5: Genetics ................................ ................................ ................................ ......72 
10.6.  Appendix 6: Liver Safety: Suggested Actions and Follow -up 
Assessments  ................................ ................................ ................................ .................... 73 
10.7.  Appendix 7: Provisions for Changes in Study Conduct During 
Exceptional Circumstances  ................................ ................................ ............................. 75 
10.8.  Appendix 8: Abbreviations and Definitions  ................................ ................................ ...79 
11. References  ................................ ................................ ................................ ...................... 84 
 
 
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
6 1. Protocol Summary  
1.1. Synopsis  
Protocol Title:   
A Phase 2, Randomized, Double -Blind, Placebo -Controlled Study to Investigate the Efficacy and 
Safety of LY38194 69 in Adults with Elevated Lipoprotein(a)  
Brief  Title:   
Efficacy and safety of LY3819469 compared with placebo in adults with elevated Lp(a)  
Regulatory Agency Identifier Number(s) :  
IND: 154938  
EU trial number: 2022 -501426 -38-00 
Rationale : 
Elevated lipoprotein(a)  (Lp[a]) is recognized as an important risk factor for cardiovascular 
disease; there are currently no approved pharmaceutical interventions for lowering Lp(a). 
LY3819469 is a novel Dicer -substrate small interfering  ribonucleic acid (siRNA ) oligonucleotide 
designed to reduce the levels of LPA mRNA and apolipoprotein(a) ( Apo[a]) expression  and 
thereby [CONTACT_170254](a) . In Phase 1 Study J3L -MC-EZEA, single subcutaneous (SC) doses of 
LY3819469 significantly and durably decreased Lp(a) and no safety issues were identified. This 
Phase [ADDRESS_199236] of a range of LY3819469  doses on Lp(a) level and 
on safety in a larger population of participants with elev ated Lp(a) to  enable Phase 3  
development of  this compound . 
Objectives , Endpoint s, and Estimands:  
Objectives  Endpoints  
Primary   
 To evaluate if LY3819469 is superior to 
placebo in percent Lp(a) reduction   Percent change from baseline in 
time-averaged Lp(a) over Days 60 -
180 
Secondary   
 To evaluate if LY3819469 is superior to 
placebo in percent Lp(a) reduction over 
Days 240 -360  Percent change from baseline in 
time-averaged Lp(a) over Days 240 -
360 
 Compare proportion of participants on 
LY3819469 versus placebo  achieving 
Lp(a) threshold levels   Proportion of participants achieving 
Lp(a) <125  and <75 nmol/L at Days 
60, 180, 240, 360, and 540  
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
7 Objectives  Endpoints  
 Compare the effect of LY3819469 to 
placebo on cardiovascular biomarkers   Percent change from baseline to 
Days 60, 180, 240, 360, and 540 for  
o Lp(a)  
o ApoB  
o hsCRP  
 Characterize the PK of LY3819469   Population PK parameters  
Abbreviations: ApoB = apolipoprotein B ; hsCRP = high-sensitivity C -reactive protein ; Lp(a)_= lipoprotein(a) ; 
PK = pharmacokinetics.  
Estimand s 
The primary clinical  question of interest is: What is the  study  intervention difference in percent 
change from baseline in time -averaged Lp(a) over Days 60 -180 of study intervention in 
participants who meet the enrollment  criteria  regardless of treatment discontinuation for a ny 
reason ? 
A similar estimand as the estimand for the primary objective will be used for the secondary 
objectives . 
Unless specified otherwise, safety assessments will be guided by [CONTACT_170255] 3819469  doses with placebo irrespective of  adherence to study intervention . 
Overall Design  
Study is a parallel, double -blinded, placebo -controlled, dose -finding, Phase 2 study of 
LY3819469 in participants with elevated Lp(a).  
Approximately 254 participants will be randomized in a 1:2:2:2 :2 ratio t o 1 of the following 
arms:  
 Arm A: 16-mg LY3819469, doses at randomization and Day 180  
 Arm B: 96-mg LY3819469, doses at randomization and Day 180  
 Arm C: 400-mg LY3819469, doses at randomization and Day 180  
 Arm D: 400-mg LY3819469, dosed at randomization, placebo at Day 180  
 Arm E: placebo, dose s at randomization and Day 180  
Brief Summary : 
The purpose of this study  is to measure difference in percent change from baseline in time-
averaged Lp(a) on over Days 60-180 with LY3819469  versus placebo in participants with 
elevated Lp(a).  
Study details include:  
● The study duration will be up to  20 months . 
● The treatment duration will include doses at the randomization visit and at Day 180 . 
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
8 Study Population : 
The study will include  adults at least [ADDRESS_199237] ce rtain 
abnormal laboratory values will not be included.  
Number of Participant s: 
Approximately 254 participants  will be randomly assigned to study intervention . 
Intervention Groups  and Duration : 
All pa rticipants  will receive a subcutaneous injection at the randomization visit and at Day 180  
(Visit 7). LY381 9469 is formulated at a concentration of 160 mg/mL.  
Arm A  Arm B  Arm C  Arm D  Arm E  
Intervention Name  [CONTACT_36940]3819469  LY3819469  LY3819469  LY3819469 
and Placebo  Placeboa 
Dosage #1       
LY3819469  Solution 
(160mg/mL)  16 mg 
(0.1 mL ) 96 mg 
(0.6 mL) 400 mg  
(2.5 mL ) 400 mg  
(2.5 mL ) − 
Placebo  (0.9% sodium 
chloride solution for 
injection)  − − − − Placeboa 
Dosage #2       
LY3819469  Solution 
(160mg/mL)  16 mg 
(0.1 mL)  96 mg 
(0.6 mL)  400 mg  
(2.5 mL)  − − 
Placebo  (0.9% sodium 
chloride solution for 
injection)  − − − Placebob Placeboa 
Route of Administration  SC injection  SC injection  SC injection  SC injection  SC injection  
Authorized as defined by 
[CONTACT_170256]: EU = European Union; SC = subcutaneous . 
a Participants  in Arm E  will be randomly assigned so that each dose cohort will have a matching pla cebo cohort 
that receives the same dose volume to maintain the study blind.  
b Participants in Arm D will receive a 2.5 -ml placebo dose at Day 180 (Visit 7) . 
Ethical Considerations of Benefit/Risk : 
Based on current information, t he study medicine treatment is believed  to have more benefits 
than risks. 
Data Monitoring Committee: No 
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
9 1.2. Schema  
 
  
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
10 1.3. Schedule of Activities  (SoA)  
Period I - Optional Prescreening: The study includes an optional prescreening visit (Visit 601) as a simple way for sites to determine 
whether participants meet Lp(a) criteria, as assessed by a central laboratory assessment, before the full screening activitie s are initiated 
at Visit 1. If the participant  has not had Lp(a) measured before or is unknown, the prescreening  visit should be completed.  The 
prescreening visit can be conducted  at the study site, or remotely, for example , at a mobile healthcare or alternate  laboratory . The 
prescreening determination of Lp(a) will be described in an appropriate informed consent form (ICF). Informed consent for the  
prescreening activities will be obtained, a participant identification number will be assigned, and sample for the Lp(a) pres creening 
laboratory test will be obtained. The optional prescreening visit can be repeated 1 time (no more) per participant if the investigator 
believes the participant would meet criteria at a later time , with a minimum of 4 weeks between visits. Repeated  sampling in the 
prescreening visit will not require re -consenting or assignment of a new participant identification number. Note: If the optional 
prescreening is opted for, central laboratory testing for Lp(a) is still required as part of the screening pr ocedures conducted at Visit 1. 
Participants with Lp(a ) <175 nmol/L  at Visit 1 will not be eligible for enrollment, despi[INVESTIGATOR_170243] . A pre screening 
visit occurring l onger or shorter than 21 days ( 3 weeks ) from screening will not be cons idered a protocol deviation.  
Period II - Screening: Visit 1 procedures may be conducted over more than 1 day as long as all activities are completed prior to Visit 
2. 
Period III - Treatment and Assessment Period: All procedures (screening and baseline) need to be completed prior to the first dose of 
study intervention . For an early discontinuation (ED) from the study intervention that occurs before the last visit in treatment period, 
see the activities listed for E D in this table.  
  
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
11    Period I - 
Pre-
Screening   Period II 
- 
Screening  Period III  -– Treatment  and Assessment  Period  Participants are required to fast before 
Visits 1-12. See Section 5.3.1 . If a 
participant arrives not fasted, schedule 
the laboratory draw for another date.  
Visit number  601 1 2 3 4 5 6 7 8 9 10 11 12 ED  
Days  from 
randomization  ≤42 ≤21 — 15 30 60 120 180 210 240 300 360 540  Visit 1 procedures may be conducted 
over more  
than 1 day if all activities are 
completed within  
the allowable visit tolerance.  
Visit interval 
tolerance (days)  See Section 
1.3 — — ±3 ±3 ±3 ±7 ±7 ±7 ±7 ±7 ±7 ±[ADDRESS_199238] dose of 
study intervention.  
Ascertainm ent of 
high risk for 
cardiovascular 
events   X             High risk for cardiovascular events 
will be defined as CAD, stroke, or 
peripheral artery disease, or ASCVD 
risk equivalents (familial 
hypercholesterolemia or type 2 
diabetes ) 
Demographics    X                 Includes year of birth, sex , ethnicity 
(where permissible ), and race.  
Preexisting 
conditions and 
medical history, 
including 
relevant surgical 
history    X            
     
All conditions ongoing and relevant 
past surgical and medical history 
should be collected.  
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
12    Period I - 
Pre-
Screening   Period II 
- 
Screening  Period III  -– Treatment  and Assessment  Period  Participants are required to fast before 
Visits 1-12. See Section 5.3.1 . If a 
participant arrives not fasted, schedule 
the laboratory draw for another date.  
Visit number  601 1 2 3 4 5 6 7 8 9 10 11 12 ED  
Days  from 
randomization  ≤42 ≤21 — 15 30 60 120 180 210 240 300 360 540  Visit 1 procedures may be conducted 
over more  
than 1 day if all activities are 
completed within  
the allowable visit tolerance.  
Visit interval 
tolerance (days)  See Section 
1.3 — — ±3 ±3 ±3 ±7 ±7 ±7 ±7 ±7 ±7 ±14 ---  
Prespecified 
medical history 
(indication and 
history of 
interest)    X            
     
Prespecified medical history includes  
history of cardiovascular events . 
Prior trea tments 
for indication    X                   Relevant prior therapi[INVESTIGATOR_31430], but 
are not limited to, lipid-lowering 
medications.  
Substance use 
(alcohol, 
caffeine, and 
tobacco use)   X      X    X X    
Concomitant 
medications   X X X X X X X X X X X X X Additional data will be collected for 
medications of interest . 
AEs X X X X X X X X X X X X X X Any events that occur after signing the 
informed consent are considered AEs 
as defined ( Appendix 10.3). 
Additional data are collected for 
certain AEs.  
Physical 
Evaluation                     
Height    X                   Participant should remove shoes.  
Weight   X X     X    X X X Participant should remove shoes.  
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
13    Period I - 
Pre-
Screening   Period II 
- 
Screening  Period III  -– Treatment  and Assessment  Period  Participants are required to fast before 
Visits 1-12. See Section 5.3.1 . If a 
participant arrives not fasted, schedule 
the laboratory draw for another date.  
Visit number  601 1 2 3 4 5 6 7 8 9 10 11 12 ED  
Days  from 
randomization  ≤42 ≤21 — 15 30 60 120 180 210 240 300 360 540  Visit 1 procedures may be conducted 
over more  
than 1 day if all activities are 
completed within  
the allowable visit tolerance.  
Visit interval 
tolerance (days)  See Section 
1.3 — — ±3 ±3 ±3 ±7 ±7 ±7 ±7 ±7 ±7 ±[ADDRESS_199239] 5 minutes and before 
ECG tracing and collection of blood 
samples for laboratory testing.  
Physical 
examination   X            X X The physical exam ination  is 
performed ( excludes pelvic, rectal, 
and breast exam ination s unless 
clinically indicated ). 
Symptom -
directed physical 
assessment    X   Symptom -directed physical 
assessment will be conducted at the 
discretion of the PI [INVESTIGATOR_170244], per local regulations, as 
indicated based on participant status 
and standard of care.  
12-Lead ECG 
(local)   X      X  
  X X X Collect  single, local ECG  prior to 
collection of blood samples for 
laboratory testing, including PK 
samples. Participants should be supi[INVESTIGATOR_51941] 5 to 10 minutes 
before ECG collections and remain 
supi[INVESTIGATOR_170245]. ECGs may be repeated at 
the PI’s discretion at any visit.  See 
Section 8.2.1 . 
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
14    Period I - 
Pre-
Screening   Period II 
- 
Screening  Period III  -– Treatment  and Assessment  Period  Participants are required to fast before 
Visits 1-12. See Section 5.3.1 . If a 
participant arrives not fasted, schedule 
the laboratory draw for another date.  
Visit number  601 1 2 3 4 5 6 7 8 9 10 11 12 ED  
Days  from 
randomization  ≤42 ≤21 — 15 30 60 120 180 210 240 300 360 540  Visit 1 procedures may be conducted 
over more  
than 1 day if all activities are 
completed within  
the allowable visit tolerance.  
Visit interval 
tolerance (days)  See Section 
1.3 — — ±3 ±3 ±3 ±7 ±7 ±7 ±7 ±7 ±7 ±14 ---  
Laboratory 
Tests and 
Sample 
Collections                    
        
  
Hematology    X   X X  X X X  X X    
Clinical 
chemistry    X X X X X  X X X  X X X   
Lipid panel    X X   X  X  X  X X X   
Urinalysis     X    X  X  X  X X X   
UACR   X    X  X  X  X X X  
Serum 
pregnancy    X             Females only.   
FSH   X             Optional; performed as needed to 
confirm postmenopausal status. See 
Appendix 10.4. 
TSH   X              
HbA1c   X      X    X X X  
Lp(a)  X X X X X X X X X X X X X X   
ApoB   X X   X X X X X X X X X   
hsCRP    X X   X X X X X X X X X   
HIV screening 
test   X               
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
15    Period I - 
Pre-
Screening   Period II 
- 
Screening  Period III  -– Treatment  and Assessment  Period  Participants are required to fast before 
Visits 1-12. See Section 5.3.1 . If a 
participant arrives not fasted, schedule 
the laboratory draw for another date.  
Visit number  601 1 2 3 4 5 6 7 8 9 10 11 12 ED  
Days  from 
randomization  ≤42 ≤21 — 15 30 60 120 180 210 240 300 360 540  Visit 1 procedures may be conducted 
over more  
than 1 day if all activities are 
completed within  
the allowable visit tolerance.  
Visit interval 
tolerance (days)  See Section 
1.3 — — ±3 ±3 ±3 ±7 ±7 ±7 ±7 ±7 ±7 ±[ADDRESS_199240]  X        
     If HBsAg is negative and HBcAb is 
positive, further testing with HBV 
DNA is required. If the screening 
HBV DNA is negative, the participant 
is not excluded . See Section 8.2.4 .  
eGFR   X    X  X  X  X X X Calculated using CKD -EPI [INVESTIGATOR_12183].  
Postdose  PK 
sample     X     X  
     Visit 2: Collect 2 samples.  
 0.5 hours postdose  
 4-9 hours postdose 
(minimum  2 hours)  
Visit 7: Collect 1 sample.  
1. 24-36 hours postdose, will 
require p articipant  to return  
1 day after Visit 7 . 
Immunogenicity 
(ADA)    P X X  X P  X  X X X Visit [ADDRESS_199241] a time-matched PK sample for 
all scheduled and unscheduled 
immunogenicity  
samples.   
Visit 7 will be collected predose.  
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
16    Period I - 
Pre-
Screening   Period II 
- 
Screening  Period III  -– Treatment  and Assessment  Period  Participants are required to fast before 
Visits 1-12. See Section 5.3.1 . If a 
participant arrives not fasted, schedule 
the laboratory draw for another date.  
Visit number  601 1 2 3 4 5 6 7 8 9 10 11 12 ED  
Days  from 
randomization  ≤42 ≤21 — 15 30 60 120 180 210 240 300 360 540  Visit 1 procedures may be conducted 
over more  
than 1 day if all activities are 
completed within  
the allowable visit tolerance.  
Visit interval 
tolerance (days)  See Section 
1.3 — — ±3 ±3 ±3 ±7 ±7 ±7 ±7 ±7 ±7 ±[ADDRESS_199242] samples 
before dosing  
Optional 
genetics sample      X            Sample can be obtained at or after the 
specified visit.  See Appendix 10.5. 
Exploratory 
biomarker 
samples    X   X  X  
X  X X    
Randomization 
and Dosing                       
Register visit 
with IWRS    X X X X X X X X X X X X X Unscheduled visits are not required to 
be registered in IWRS . 
Randomization 
via IWRS      X              
Dispense study 
intervention via 
IWRS      X     X  
       
Administer  study 
intervention    X     X        
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
17 Abbreviations: ACC /AHA = American College of Cardiology /American Heart Association ; ADA = anti -drug antibody; AE = adverse event; ApoB = 
apolipoprotein b; ASCVD = atherosclerotic cardiovascular disease ; CAD = coronary artery disease ; CKD -EPI = Chronic Kidney Disease Epi[INVESTIGATOR_10427]; DNA = deoxyribonucleic acid ; ECG = electrocardiogram; ED  = early discontinuation; eGFR = estimated glomerular filtration rate; FSH = 
follicle -stimulating hormone; HbA1c = hemoglobin A1c; HBcAb  = hepatitis B core antibody ; HBsAg  = hepatitis B surface antigen ; HBV = hepatitis B virus; 
HCV = hepatitis C virus; HIV = human immunodeficiency virus; hsCRP  = high-sensitivity C -reactive protein; ICF = informed consent form; IWRS = 
Interactive Web -Response System; Lp(a) = Lipoprotein(a); P = predose ; PI = princip al investigator; PK = pharmacokin etic; RNA = ribonucleic acid; TSH = 
thyroid stimulating hormone; UACR = urine albumin creatinine ratio.  
 
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
18 2. Introduction  
LY3819469 is a novel Dicer -substrate small interfering  ribonucleic acid (siRNA ) oligonucleotide 
designed to reduce the levels of LPA mRNA and apolipoprotein(a)  (Apo[a]) expression  and 
thereby [CONTACT_170257](a)  (Lp[a]). LY3819469 is being developed to reduce the risk of 
cardiovascular events in patients with or at high  risk of atherosclerotic cardiovascular disease 
(ASCVD ) and high levels of Lp(a)  
2.1. Study Rationale  
Elevated Lp(a) is recognized as an important risk factor of cardiovascular disease; there are 
currently no approved pharmaceutical interventions for lowering L p(a). LY3819469  is an 
siRNA , that decreases Lp(a) formation and has been shown to reduce Lp(a) in preclinical studies. 
In Phase 1 Study J3L-MC-EZEA  (EZEA ) with single doses  of LY 3819469 , Lp(a) was 
significantly decreased and no safety issues were identified. This Phase [ADDRESS_199243] of a range of LY 3819469  doses on Lp(a) level and on safety in a larger 
population of participants with elevated Lp(a) to enable Phase 3 development of this compound . 
2.2. Background  
2.2.1.  Introduction to L p(a) 
Lp(a) is an atherogenic  lipoprotein consisting of a low-density lipoprotein  particle linked via a 
disulfide bond to Apo(a) (see Figure 1). 
Apo(a) is a protein found in new -world monkeys, great apes, and humans ( Utermann  1989). The 
protein, encoded by [CONTACT_170258], includes 10 unique units of kringle IV repeats; the first and 
third through tenth are present in single copi[INVESTIGATOR_170246] (1 to <50). Additionally, the protein includes a kringle V and a protease -like domain 
that is not biologically active ( Dubé et al . 2012; Kronenberg and Ute rmann 2013 ; Tsimikas  
2017).  
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
19   
Abbreviations: Apo(a) = apolipoprotein(a) ; ApoB = apolipoprotein b ; LDL = low-density lipoprotein ; 
Lp(a ) = lipoprotein(a) . 
 
Figure 1. Representation of Lp(a) particle . 
Lp(a) contains oxidized phospholipi[INVESTIGATOR_805]. Plasma levels of Lp(a) are genetically determined. 
Single -nucleotide polymorphisms (SNPs) of the LPA gene are associated with higher or lower 
Lp(a) levels; for example, rs10455872 and rs3798220 are associated with increased Lp(a) 
(Clarke  et al. 2009; Li et al. 2011 ). Additionally, the number of kringle IV2 repeats determines 
protein size, which is inversely proportional to plasma concentration and mass of Lp(a); larger 
Apo(a) size is associated with lower concentrations of Lp(a).  Despi[INVESTIGATOR_170247](a) concentrations between individuals, intra -patient variability in Lp(a) is low 
and is not thought to be materially impacted by [CONTACT_17977], environmental factors, or exercise ( Schmidt  
et al. 2016). However, Apo(a) is an acute -phase reactant, and Lp(a) increases, for example, after 
surgery, myocardial infarction, and infection ( Maeda  et al. 1989; Noma et al. 1994 ; Min et al. 
1997) . 
2.2.2.  Elevated Levels of Lp(a) Are Associated with Increased Risk of Cardiovascular 
Disease  
Lp(a) particles are thought to exert adverse cardiovascular effects through atherogenic, 
inflammatory, and possibly pro-thrombotic activity ( Tsimikas  2017).  
In a meta -analysis of 36 studies, Lp(a) was associated with risk for nonfatal myocardial 
infarction or co ronary death ( Emerging Risk Factors Collaboration  et al. 2009) . In studies of 
LPA gene KIV2  repeats or SNPs, genetic variants conferring higher levels of Lp(a) were found 
to be related to risk for myocardial infarction and coronary disease in Mendelian ran domization 
and genome -wide association studies ( Clarke  et al. 2009; Kamstrup  et al. 2009).  In a study 
including data from the [LOCATION_008] ([LOCATION_006]) Biobank, 7 genome -wide association studies, and 
LPA sequencing, Lp(a) was associated with risk of coronary hea rt disease, stroke, chronic kidney 
disease, aortic valve stenosis, heart failure, and peripheral vascular disease ( Emdin  et al. 2016).  
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
20 The American Heart Association and American College of Cardiology  Guideline on the 
management of blood cholesterol defined Lp(a) ≥50  mg/dL or ≥125  nmol/ L as risk enhancing in 
2018 ( Grundy  et al. 2019).  Elevated Lp(a) >50  mg/dL was present in 24% of samples from a 
reference laboratory and 29.2% of samples from a tertiary care center ( Varvel  et al. 2016).  The 
estimated p revalence of Lp(a) >60  mg/dL is 64 million in the [LOCATION_002], 150 million in 
Europe, and 1.4 billion worldwide ( Tsimikas and Stroes  2020).  
2.2.3.  Available  Treatments  
Lipid apheresis is approved and used in some geographies for patients with elevated Lp(a) 
(Jaeger et al. 2009; Nugent et al. 2020). Proprotein convertase subtilisi n/kexin type 9 (PCSK9) 
inhibitors, alirocumab , evolocumab, and inclisiran, reduce Lp(a) by [CONTACT_3450] 25% 
(Robinson et al. 2015; Sabatine et al. 2015 ; Stoekenbroek  et al. 2019 ), and prescription -strength 
niacin also produces 15% to 25% reductions in Lp(a)  (AIM -HIGH Investigators 2011; HPS2 -
THRIVE Collaborative Group  2014), but are not approved treatments  for Lp(a) reduction. Novel 
treatments to reduce Lp(a) are under investigation , including an antisense oligonucleotide 
(pelacarsen ), and 2 siRNA therapi[INVESTIGATOR_014] (olpasiran and SLN360), which ha ve been shown to lower 
Lp(a) concentrations in clinical trials (Viney et al. 2016 ; Tsimikas et al 2020 ; Ference 2022; 
Koren et al. 2022 ; Nissen  et al. 2022 ). 
2.2.4.  Introduction to LY 3819469  
LY3819469 inhibit s the production of Apo(a) by  [CONTACT_170259].  LY3819469 reduces steady -state levels of Apo(a)  protein  in a mouse model 
transgen ic for human Apo(a), and Lp(a) in cynomolgus monkeys that endogenously express 
Lp(a).  
Nonclinical toxicology studies  of LY3819469  showed no notable adverse drug effects.   
In Phase 1 Study EZEA of participants treated with single LY3819469 doses up to 608 mg, 
Lp(a) was lowered  and no notable adverse drug effects were observed .  
Efficacy will be determined by [CONTACT_170260](a)  in this Phase 2 study  to 
enable dose selection for Phase 3 study .  
2.3. Benefit/Risk Assessment  
More detail ed information about the known and expected benefits and risks and reasonably 
expected  adverse events (AEs) of LY381946 9 may be found in the Investigator’s Brochure  (IB) 
or Development Safety Update Report .  
2.3.1.  Risk Assessment  
Study Intervention  
The pharmacodynamic (PD) effect of LY3819469  is anticipated to be lowering of Lp(a). Lp(a) 
serves no known positive functions and is not present in most species. Additionally, people  
homozygous for null mutations of the LPA gene have not been identified to hav e any related 
health issues. Furthermore, toxicology studies of LY3819469 have shown no notable adverse 
effects. Finally, human Phase 1 Study EZEA showed that single LY3819469 doses up to 608 mg 
were safe and generally well tolerated by [CONTACT_170261].  
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
21 Study Procedures  
The study will include blood draws and safety monitoring, and these procedures are not 
anticipated to be associated with significant participant risk. 
2.3.2.  Benefit Assessment  
Lp(a)  is a lipoprotein particle with atherogenic, inflammatory, and possibly pro -thrombotic 
activity. In preclinical studies and a previous Phase 1 study , LY3819469  decrease d Lp(a). 
Lowering of Lp(a) is anticipated to have beneficial effects on cardiovascular dise ase; h owever, 
the duration of  lowering of Lp(a) in this study may not be sufficient to confer any benefits. 
Nevertheless, participants  may benefit by [CONTACT_170262].  
2.3.3.  Overall Benefit Risk Conclusion  
Treatment with study intervention  is anticipated to have a n acceptable  benefit to risk profile.  
 
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
22 3. Objectives , Endpoints , and Estimands  
Objectives  Endpoints  
Primary   
 To evaluate if LY3819469 is superior 
to placebo in percent Lp(a) reduction   Percent change from baseline in time-
averaged  Lp(a) over Days 60 -180 
Secondary   
 To evaluate if LY3819469 is superior 
to placebo in percent Lp(a) reduction  
over Days 240 -360  Percent change from baseline in ti me-
averaged Lp(a) over Days 240 -360 
 Compare proportion of participants on  
LY3819469 versus placebo achieving  
Lp(a)  threshold levels   Proportion of participants achieving 
Lp(a) <125  and <75 nmol/L at Days 
60, 180, 240, 360, and 540  
 Compare the effect  of LY 3819469  to 
placebo  on cardiovascular biomarkers   Percent change from baseline to Days 
60, 180, 240, 360, and 540  for 
o Lp(a)  
o ApoB  
o hsCRP   
 Characterize the PK of LY3819469   Population PK parameters   
Exploratory   
 To evaluate if LY3819469 is superior 
to placebo in absolute change from 
baseline   Absolute change from baseline in 
Lp(a) at Days 60, 180, 240, 360, and 
540 
 Compare proportion of participants on  
LY3819469 versus placebo achieving 
absolute lowering of Lp(a)  threshold   Proportion of participants ach ieving 
Lp(a) lowering of at least 150  nmol/L 
at Days 60, 180, 240, 360, and 540  
 Compare the lipid profile in response 
to LY3819469  versus  placebo   Lipid profile  
o LDL -C 
o total cholesterol  
o HDL -C 
o triglycerides  
 Evaluation of immunogenicity.   Incidence of treatment -emergent 
ADA s.  
Abbreviations: ADA = anti -drug antibod y; ApoB = apolipoprotein B ; HDL -C = high -density lipoprotein -
cholesterol ; hsCRP = high-sensitivity C -reactive protein ; LDL -C = low-density lipoprotein -cholesterol ; 
Lp(a)  = Lipoprotein(a) ; PK = pharmacokinetics.  
Approved on [ADDRESS_199244] is: What is the intervention difference in  percent change 
from baseline in time-averaged Lp(a) over Days 60 -180 of study intervention in participants who 
meet the inclusion criteria regardless of treatment discontinuation for any reason?  
The primary estimand characterizes the treatment effect regardless of intercurrent events and is 
named the “treatment -regimen estimand .” 
The treatment -regimen estimand is described by [CONTACT_170263]:  
Population : participants who meet the enrollment criteria. Further details can be found in Section 
5. 
Endpoint: percent change from baseline in time -averaged Lp(a) over Days 60 -180 which will be 
calculated by [CONTACT_170264] ( AUC ) between Day 60 to Day 180 divided by 120 . 
Treatment condition: the randomized treatment with allowance for safety.  Further  details on 
study interventions, and concomitant interventions can be found in Section  6.  
There are no intercurrent events. Since each patient can only take one dose for the first 6 months, 
there is no intercurrent events of treatment discontinuation. The concomitant medication  use is 
not considered intercurrent events as it  is considered as a part of patient management .  
Population -level summary: mean percent changes in Lp(a).  
Treatment contrast of interest : difference in mean percent changes in Lp(a) between LY3819469 
and placebo.  
Ratio nale for estimand: this estimand aims to study the efficacy of LY3819469 that reflects the 
real-life behavior of the target population . 
Estimand (s) for secondary objective  
A similar  estimand for the primary objective will be used for the secondary clinical response 
before the second injection  at Day 180 . For the objectives after Day 180 , the treatment 
discontinuation will be handled by [CONTACT_170265].  
Unless specified otherwise, safety assessments will be guided by [CONTACT_170255]3819469 doses with placebo irrespective of adherence to study intervention . 
 
 
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
24 4. Study Design  
4.1. Overall  Design  
Study EZEB  is a parallel, double -blinded, placeb o-controlled, dose-finding, Phase 2 study of  
LY3819469  in participants with elevated Lp(a).  
Approximately 254 participants will be randomized in a 1:2:2:2:2 ratio to 1 of the following 
arms:  
 Arm A: 16-mg LY3819469 dosed at randomization and Day 180  
 Arm B: 96-mg LY3819469 dosed at randomization and Day 180  
 Arm C: 400-mg LY3819469 dosed at randomization and Day 180  
 Arm D: 400-mg LY3819469 dosed at randomization, and placebo at Day 180  
 Arm E: place bo doses at randomization and Day 180  
Treatment periods and assessments are described in the Schedule  of Activities  (SoA) (Section 
1.3) 
The study schema is shown in Section  1.2. 
The study population is described in Sec tion 5.  
The e fficacy and safety assessments  are described in Sections 8.1 and 8.2, respectively.  
4.2. Scientific Rationale for Study Design  
Interim data from  Phase 1 Study EZEA  showed a decrease in Lp(a) in healthy participants with 
Lp(a) levels ≥75  nmol/L or ≥30  mg/dL given single doses of LY3819469. The current study is 
intended to be Phase 3 enabling , as it will provide the following information:  
 Efficacy and safety data with subcutaneous (SC)  administration of doses of study drug at 
randomization and Day 180  in participants with higher levels of Lp(a). This design  is 
anticipated to provide information  regarding the maximal level and durability of lowering 
of Lp(a) with LY3819469 and information regarding an appropriate dose and dosing 
frequency  of study drug for Phase 3. The primary endpoint is over Days 60 -180 to assess 
the lowering of  Lp(a) across ti me. 
 Participants for this study will have Lp(a) ≥175  nmol/L at baseline. This study will thus 
provide relevant efficacy and safety for participants with Lp(a) sufficiently high to 
participate in a Phase 3 cardiovascular outcomes trial.  
The study includes a n optional prescreening Visit 601 where potential participants can be 
prescreened with an assessment of Lp(a).  
Participants qualifying based on the optional prescreening assessment and those known to have a 
significantly elevated Lp(a) can be screened for inclusion in the trial at Visit 1.  
Placebo is chosen as the control treatment to assess whether any observed effects are treatment 
related or simply reflect the study conditions. The double -blind design minimizes bias.  
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
25 In this study, collection of demographic information includes race and ethnicity. The scientific 
rationale is based on the need to assess variable response in safety and/or efficacy based on race 
or ethnicity. This question can be answered only if all the relevant data are collected.  
4.2.1.  Participant Input into Design  
Throughout this protocol, the term "participant" is used to indicate an individual who participates 
in a clinical trial, either as a recipi[INVESTIGATOR_170248] a control. This 
usage reflects preferences  indicated by [CONTACT_170266].  
4.3. Justification for Dose  
LY3819469  doses of 16 mg, 96 mg, and 400  mg, administered subcutaneously, were selected 
based on the following:  
 Safety an d tolerability of LY3819469  doses up to 608  mg in healthy participants in the 
Phase 1 Study EZEA  
 The selected dose levels and dose range support a robust dose -exposure –response 
analysis of multiple safety and efficacy measures to support selection of dose( s) of 
LY3819469 with optimal benefit/risk ratio for further clinical development  
4.4. End of Study  Definition  
The end of the study is defined as the date of the last visit of the last participant in the study or 
last scheduled procedure shown in the SoA for the  last participant in the trial globally.  
A participant is considered to have completed the study if the participant has completed all 
periods of the study including the last visit or the last scheduled procedure shown in the SoA.  
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
26 5. Study Population  
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, is not permitted.   
Presence or absence of high risk for cardiovascular events will be a factor for stratification of the 
randomization.  High risk for cardiovascular events will be defined as coronary artery disease 
(CAD), stroke, or peripheral artery disease , or ASCVD risk equivalents (familial 
hypercholesterolemia or type 2 diabetes).  
5.1. Inclusion Criteria  
Participants are eligible to be included in the study only if all of the following criteria apply:  
Age 
1. Participants must be at least 40 years old at the time of signing the informed consent.  
Type of Participant and Disease Characteristics  
2. Participants with Lp(a) ≥ 175 nmol/ L at Visit 1, measured at the central laboratory.  
3. Participants  on the following medications according to local practice must be on a stable 
regimen for at least 4 weeks prior to Visit 1  and expected to remain on a stable regimen 
through the end of the Treatment and Assessment Period : 
a. lipid-lowering drugs ( such as statins, ezetimibe, PCSK9 inhibitors, prescription -
dose niacin, fibrates, fish oil , or other products containing omega -3 fatty acids , 
including over-the-counter [ OTC ] preparations)  
b. testosterone, estrogens, anti-estrogens, progest ins, selective estrogen receptor 
modulators , or growth hormone  
Weight  
4. Have a  body mass index within the range 18.5 to 40  kg/m2, inclusive.  
Sex and Contraceptive/Barrier Requirements  
5. Male and/or female   
a. Males who agree to use highly effective/effective methods of contraception may 
participate in this trial.  
b. Women of childbearing potential (WOCBP) are excluded from the trial.  
c. Women not of childbearing potential (WNOCBP) may participate in this trial.  
Please refer to  Appendix 10.4 for definitions  and additional guidance related to 
contraception.  
Contraceptive use by [CONTACT_170267] c onsistent with local regulations regarding 
the methods of contraception for those par ticipating in clinical studies.  For the 
contraception requirements of this protocol, see Appendix 10.4. 
Informed  Consent  
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
27 6. Capable of giving signed informed consent as described in Appendix 1  (Section 10.1), 
which includes compliance with the requirements and restrictions listed in the informed 
consent form (ICF) and in this protocol . 
Other Inclusions  
7. Are reliable and willing to make themselves available for the duration of the study and 
are willing to follow study procedures , in the opi[INVESTIGATOR_871].  
5.2. Exclusion Criteria   
Participants are excluded from the study if any of the following criteria apply:  
Medical Conditions  
8. Have a history or presence of an underlying diseas e, or surgical, physical, medical , or 
psychiatric  condition that, in the opi[INVESTIGATOR_871] , would potentially affect 
participant safety within the study or interfere with participating in or completing the 
study or with the interpretation of data . 
9. Any of the following , or other events indicating unstable medical condition in the opi[INVESTIGATOR_8574], within 3 months of Visit 1 : 
a. major surgery  
b. coronary, carotid, or peripheral arterial revascularization  
c. stroke  or transient ischemic attack  
d. myocardial  infarction or unstable angina  
e. acute limb ischemia.  
10. Have, in the [ADDRESS_199245] a 
hemoglobin A1c (HbA1c) ≥8% at Visit [ADDRESS_199246] uncontrolled hypertension with a resting blood pressure ≥1 60 mm Hg systolic 
and/or ≥100  mm Hg diastolic  at Visit 1;  a repeat measure is allowed.  
12. [LOCATION_001] Health Association Class III or IV heart failure or last known left ventricu lar 
ejection fraction <30%.  
13. Active  or acute  infection requiring systemic antiviral or antimicrobial therapy that will 
not be completed prior to Visit 2.  
14. Malignancy within [ADDRESS_199247] a current infection with hepatitis B vi rus (HBV ), that is, positive for hepatitis B 
surface antigen (HBsAg ) and/or polymerase chain reaction ( PCR ) positive for HBV 
deoxyribonucleic acid (DNA ) (Section 8.2.4 ). 
19. Have a current infection with hepatitis C virus  (HCV ), that is, positive for HCV 
ribonucleic acid  (RNA ) (Section  8.2.5 ). 
20. Have human immunodeficiency virus (HIV) infection.  
Prior/ Concomitant Therapy  
21. Lipoprotein apheresis within 3 months of Visit 1 , or planned during the study . 
22. Treatment with another investigational drug, biological agent, or device within 1 month 
of Visit 1 , or 5 half -lives of investigational agent, whichever is longer.  
23. Treatment with any oligonucleotide or siRNA within 9 months of Visit 1 . 
Prior/Concurrent Clin ical Study Experience  
24. Are currently enrolled in any other clinical study involving an investigational product or 
any other type of medical research judged not to be scientifically or medically compatible 
with this study.  
Diagnostic Assessments  
25. Clinically  significant abnormalities in screening laboratory values that would render a 
participant unsuitable for inclusion in the opi[INVESTIGATOR_871] . 
26. Any of the following abnormalities:  
a. estimated glomerular filtration rate  (eGFR ) ˂30 mL/min/1.73  m2 
b. alanine  aminotransferase (ALT) or aspartate aminotransferase (AST) >3.0 x upper 
limit of normal ( ULN ) 
c. bilirubin > 1.5x ULN, except for participants diagnosed with  Gilbert’s syndrome  
Other Exclusions  
27. Are Eli Lilly  and Company (Lilly)  employees, or are employees of any third  party 
involved in a study that require s exclusion of their employees . 
28. Are investigator site personnel directly affiliated with this study and/or their immediate 
families. Immediate family is defined as a spouse, parent, child, or sibling, whether 
biological or legally adopted . 
29. Are pregnant, or intend to become pregnant or to br eastfeed during the study . 
30. Are, in the judgment of the investigator, actively suicidal and therefore deemed to be at 
significant risk for suicide . 
5.3. Lifestyle Considerations  
5.3.1.  Meals and Dietary Restrictions  
Participants are required to fast for at least [ADDRESS_199248] 10 hours. Fasting is not required for 
postdose pharmacokinetic ( PK) sample s. During preparation for fasting samples, the participant 
can drink water and they should ensure that they consume sufficient water in order to not become 
Approved on [ADDRESS_199249] taken for safety reasons; these may be taken without regard to fasting status.  
5.3.2.  Blood Donation  
Participants must not donate blood for the duration of the study.  
5.4. Screen Failures  
A screen failure occurs  when a participant  who consent s to parti cipate in the clinical study  is not 
subsequently randomly assigned to study intervention . A minimal set of screen failure 
information is required to ensure transparent reporting of screen failure participant s to meet the 
Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to 
respond to queries from regulatory authorities. Minimal information includes demography, 
screen failure details, eligibility criteria, and any serious adverse  event  (SAE) .  
Individuals who do not meet the criteria for participation in this study (screen failure) may be 
rescreened once if the investigator believes the participant would meet criteria at a later time. 
Rescreened participants should be assigned a n ew participant number for every screening or 
rescreening event.  
5.5. Criteria for Temporarily Delaying 
Enrollment/Randomization/Administration of Study Intervention of 
a Participant  
Not applicable.  
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
30 6. Study Intervention (s) and Concomitant Therapy  
Study intervention is defined as an y investigational intervention (s), marketed product(s), 
placebo , or medical device (s) intended to be administered to /used by  a study participant 
according to the study protocol.   
6.1. Study Intervention(s) Administered  
Arm A  Arm B  Arm C  Arm D  Arm E  
Intervention Name  [CONTACT_36940]3819469  LY3819469  LY3819469  LY3819469 
and Placebo  Placeboa 
Dosage #1       
LY3819469  Solution (160  
mg/mL)  16 mg 
(0.1 mL)  96 mg 
(0.6 mL)  400 mg  
(2.5 mL)  400 mg  
(2.5 mL)  − 
Placebo  (0.9% sodium 
chloride solution for 
injection)  − − − − Placeboa 
Dosage #2       
LY3819469  Solution (160  
mg/mL)  16 mg 
(0.1 mL)  96 mg 
(0.6 mL)  400 mg  
(2.5 mL)  − − 
Placebo  (0.9% sodium 
chloride solution for 
injection)  − − − Placebob Placeboa 
Route of Administration  SC injection  SC injection  SC injection  SC injection  SC injection  
Authorized as defined by 
[CONTACT_170268]: EU = European Union; SC = subcutaneous.  
a Participants  in Arm E  will be randomly assigned so that each dose cohort will have a matching placebo cohort 
that receives the same dose volume to maintain the study blind.  
b Participants in Arm D will receive a 2.5-ml placebo dose at Day 180 (Visit 7) . 
The table  below  describes the injection volume for the different intervention dose groups.  
Intervention Group  Injection volume  
[ADDRESS_199250] be stored in a secure, environmentally controlled, and monitored 
(manual or automated) area in accordance with the labeled storage conditions with access 
limited to the investigator and authorized  study personnel . 
3. The investigator  or authorized stu dy personnel are  responsible for study intervention 
accountability, reconciliation, and record maintenance ( that is,  receipt, reconciliation, and 
final disposition records).  
4. Further guidance and information for the final disposition of unused study interve ntions 
will be  provided separately .  
6.3. Measures to Minimize Bias: Randomization and Blinding  
All participants will be centrally assigned to randomized study intervention using an Interactive 
Web -Response System (IWRS).  Participants will be stratified by [CONTACT_170269] (yes/no)  and baseline Lp(a) ( <275 nmol/L , ≥275 nmol/L ). Placebo participants will be 
randomly assigned so that each dose cohort will have a matching placebo cohort that receives the 
same dose volume to maintain the study bli nd. Before the study is initiated, the log in 
information and directions for the IWRS will be provided to each site. 
Study intervention will be dispensed and administered at the study visits summarized in SoA.  
This is a double -blind study in which particip ants are blinded to study intervention.  The IWRS 
will be programmed with blind -breaking instructions. In case of an emergency, the investigator 
has the sole responsibility for determining if unblinding of a participants’ intervention  
assignment is warrante d. Participant safety must always be the first consideration in making such 
a determination. If the investigator decides that unblinding is warranted, the investigator should 
make every effort to contact [CONTACT_1152] a participant’s intervention  
assignment unless this could delay emergency treatment for the participant. If a participant’s 
intervention  assignment is unblinded, the sponsor must be notified immediately  within [ADDRESS_199251] be recorded.  
If an investigator , site personnel performing assessments, or participant is unblinded, the 
participant may be continued in the study.  
Investigators will remain blinded to each participant’s assigned study intervention throughout the 
course of the study. To maintain this blind, an otherwise uninvolved third party will be 
responsible for the preparation  and dispensation of all study interv ention and will endeavor to 
ensure that there are no differences in time taken to dispense following randomization.  
This third party will instruct the participant to avoid discussing the volume of injection, dosing 
frequency , or packaging of the study intervention with the investigator.  
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
32 In the event of a quality assurance audit, the auditor(s) will be allowed access to unblinded study 
intervention records at the site(s) to verify that randomization/dispensing has been done 
accurately.  
6.4. Study Intervention Compliance  
Study intervention will be administered under medical supervision by [CONTACT_170270]. The study intervention and study participant identification will be confirmed prior to 
the time of dosing. The date an d time of each dose administered will be recorded in the source 
documents and in the case report form ( CRF ). 
6.5. Dose Modification  
This protocol does not allow dose adjustments . 
6.6. Continued Access to Study Intervention after the End of the Study  
LY3819469  will n ot be made available to participants after completion of the study.  
6.7. Treatment of Overdose  
For this stu dy, any dose of  LY3819469  greater than the planned dose will be considered an 
overdose.  
Sponsor does not recommend specific treatment for an overdose . 
In the event of an overdose, the investigator/treating physician should : 
● Contact [CONTACT_10990].  
● Evaluate the participant to determine, in consultation with the medical monitor, 
whether study intervention should be interrupte d or whether the dose should be 
reduced.  
● Closely monitor the participant for any AE/SAE and laboratory abnormalities 
until study intervention  no longer has a clinical effect or can no longer be detected 
systemically (at least 2 days). 
6.8. Concomitant Therapy  
Any medication or vaccine , including OTC  or prescription medicines, vitamins, and/or herbal 
supplements , that the participant is receiving at the time of enrollment or receives during the 
study must be recorded along with 
● reason for use  
● dates of administration including start and end dates , and  
● dosage information including dose and frequency for concomitant therapy of 
special interest.  
The medical monitor should be contact[CONTACT_63193].  
Approved on [ADDRESS_199252] 4 weeks prior to screening and expected to remain on a stable regimen through the 
end of the Treatment and Assessment Period , unless changes need to be made because of AEs: 
 lipid-lowering drugs ( such as statins, ezetimibe, PCSK9 inhibitors, prescription -dose 
niacin, fibrates, fish oil, or other products containing omega -3 fatty acids, including OTC 
preparations), and  
 testosterone, estrogens, progesterone, growth hormone, or progestins.  
 
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
34 7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal  
Discontinuation of specific sites or of the study as a whole are handled as part of Appendix 1  
(Section 10.1). 
7.1. Discontinuation of Study Intervention  
When  necessary , a participant may be permanently discontinue d from  study intervention . If so, 
the participant will remain in the study and follow procedures for remaining study visits , as 
shown in the SoA .  
A participant should be permanently discontinued from study intervention if  
 the participant becomes pregnant during the study  
 in the opi[INVESTIGATOR_144457], the participant should permanently discontinue the 
study intervention for safety reasons  
 if the investigator determines that a systemic hypersensitivity reaction has occurred 
related to study intervention adm inistration, the participant may be permanently 
discontinued from the study intervention, and the sponsor’s designated medical monitor 
should be notified. If the investigator is uncertain about whether a systemic 
hypersensitivity reaction has occurred and whether discontinuation of study intervention 
is warranted, the investigator may consult the sponsor  
 the participant has an AE or an SAE or a clinically significant change in a laboratory 
value that, in the opi[INVESTIGATOR_871], merits discontinuati on of study intervention 
and appropriate measures being taken  
 if the participant experiences a hepatic event or liver test abnormality as specified in the 
liver chemistry stoppi[INVESTIGATOR_3418] (see Section 7.1.1 ), and  
 HBV or HCV: The participant tests positive for HBV DNA (see Section 8.2.4 ) or tests 
positive for HCV RNA (Section 8.2.5 ). 
Note: The HBV DNA result is to be confirmed if initial positive test result is positive 
but below t he level of quantification. Prior to discontinuation of any 
immunomodulatory and/or immunosuppressive therapy, including study intervention, 
the participant is to be referred to, evaluated, and managed by a specialist physician 
with expertise in evaluation  and management of viral hepatitis. The timing of 
discontinuation from study intervention relative to the initiation of any antiviral 
treatment for hepatitis is to be based on the recommendation of the consulting 
specialist physician, in conjunction with t he investigator, and aligned with medical 
guidelines and standard of care.  
Approved on [ADDRESS_199253] elevations in participants with normal or near -
normal  baseline liver tests  
In study participants with n ormal or near-normal baseline liver tests (ALT, AST, alkaline 
phosphatase [ALP ] <1.5x ULN), the  study drug should be interrupted  or discontinued  and close 
hepatic monitoring initiate d (see Appendix 10.6) if one or more of these conditions occur:  
Elevation  Exception  
ALT or AST >8x ULN   
ALT or AST >5x ULN for more than [ADDRESS_199254] >3x ULN and either TBL >2x ULN or INR >1.5  For participants with Gilbert’s syndrome:  
If baseline direct bilirubin is >0.5 mg/dL, 
then doubling of direct bilirubin should be 
used for drug interruption decisions rather 
than TBL  >2x ULN.  
ALT or AST >3x ULN with the appearance of fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, rash, 
and/or eosinophilia (>5%)   
ALP >3x ULN, when the source of increased ALP is the liver   
ALP >2.5x ULN and TBL >2x ULN  For participants with Gilbert’s syndrome:  
If baseline direct bilirubin is >0.5 mg/dL, 
then doubling of direct bilirubin should be 
used for drug interruption decisions rather 
than TBL  >2x ULN.  
ALP >2.5x ULN with the appearance of fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, rash, 
and/or eosinophilia  (>5%)   
Source: FDA Guidance for Industry: Drug -Induced Liver Injury: Premarketing Clinical Evaluation, July 2009 
and other consensus guidelines, with minor modifications  
Abbreviations: ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; 
FDA = Food and Drug Administration; INR = international normalized ratio; TBL = total bilirubin; ULN= upper 
limit of normal . 
 
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
36 Interrupting study drug based on elevated liver tests in participants with abnormal 
baseline liver tes ts 
In study participants with abnormal baseline liver tests (ALT, AST, ALP ≥1.5x ULN), the study 
drug should be interrupted  or discontinued  if one or more of these conditions occur :  
Elevation  Exception  
ALT or AST >4x baseline   
ALT or AST >3x baseline for more than [ADDRESS_199255] >2x baseline and either TBL >2x ULN or INR 
>1.5  For participants with Gilbert’s syndrome:  
If baseline direct bilirubin is >0.5 mg/dL, 
then doubling of direct bilirubin should be 
used for drug interruption decisions rath er 
than TBL  >2x ULN.  
ALT or AST >2x baseline with the appearance of fatigue, 
nausea, vomiting, right upper quadrant pain or tenderness, 
fever, rash, and/or eosinophilia (>5%)   
ALP >2.5x baseline, when the source of increased ALP is the 
liver  
ALP >2x ba seline and TBL >2x ULN  For participants with Gilbert’s syndrome:  
If baseline direct bilirubin is >0.5 mg/dL, 
then doubling of direct bilirubin should be 
used for drug interruption decisions rather 
than TBL  >2x ULN.  
ALP >2x baseline with the appearance of  fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, rash, 
and/or eosinophilia (>5%)   
Source: FDA Guidance for Industry: Drug -Induced Liver Injury: Premarketing Clinical Evaluation, July 2009 
and other consensus guidelines, with minor modifications  
Abbreviations: ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; 
FDA = Food and Drug Administration; INR = international normalized ratio; TBL = total bilirubin; ULN= upper 
limit of normal . 
Resuming study drug after elevated liver tests  
Resumption of the study drug can be considered only in consultation with the Lilly -designated  
medical monitor and only if the liver test results return to baseline and if a self-limited  nondrug  
etiology is ide ntified. Otherwise, the study drug should be discontinued.  
7.1.2.  QTc Stoppi[INVESTIGATOR_42224] a clinically significant finding is identified (including, but not limited to changes from baseline 
in QT interval corrected using Fridericia’s formula (QTcF ) after enrollment, the investigator or 
qualified designee will determine if the participant  can continue in the study  and if any change in 
participant  management is needed . This review of the electrocardiogram ( ECG ) printed at the 
time of collection  must be documented . Any new clinically relevant finding should be reported 
as an AE.  
7.2. Participant Discontinuation/ Withdrawal from the Study  
Discontinuation is expected to be uncommon.  
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
37 A participant  may withdraw from the study : 
● at any time at the participant’s  own request  
● at the request of the participant’s  designee (for example, parents or legal 
guardian)  
● at the discretion of the investigator for safety, behavioral, compliance, or 
administrative reasons  
● if enrolled  in any other clinical study involving an investigational product , or 
enrolled  in any other type of medical research judged not to be scientifically or 
medically compatible with this study  
At the time of discontinuing from the study, if possible,  the participant will complete  procedures 
for an early discontinuation ( ED) visit, as shown in the S oA. If the participant has not already 
discontinued the study intervention, the participant will be permanently discontinued from the 
study intervention at the t ime of the decision to discontinue the study.  
If the participant  withdraws consent  for disclos ure of future information, the s ponsor may retain 
and continue to use any data collected before such a withdrawal of consent . If a participant  
withdraws from the study, the participant  may request destruction of any samples taken and not 
tested , and the investigator must document this in the site study records . 
7.3. Lost to Follow -up 
A participant will be considered lost to follow -up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contact[CONTACT_9298]. Site personnel or designee are 
expected to make diligent attempts to contact [CONTACT_10971] a scheduled visit 
or were otherwise una ble to be followed up by [CONTACT_779].   
Site personnel, or an independent third party, will attempt to collect the vital status of the 
participant within legal and ethical boundaries for all participants randomized, including those 
who did not get investigatio nal product. Public sources may be searched for vital status 
information. If vital status is determined  to be deceased , this will be documented and the 
participant will not be considered lost to follow -up. Sponsor personnel will not be involved in 
any atte mpts to collect vital status information . 
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
38 8. Study Assessments and Procedures  
● Study procedures and their timing are summarized in the SoA.   
● Immediate  safety concerns  should be discussed with the s ponsor immediately 
upon occurrence or awareness to determine if the participant should continue or 
discontinue study intervention . 
● Adherence to the study design requirements, including those specified in the SoA, 
is essential and required for study condu ct. 
● All screening evaluations must be completed and reviewed to confirm that  
potential participant s meet all eligibility criteria. The investigator will maintain a 
screening log to record details of all participant s screened and to confirm 
eligibility or  record reasons for sc reening failure, as applicable.   
8.1. Efficacy Assessments  
See Section 9.3 for definitions of the efficacy endpoints . 
8.1.1.  Primary Efficacy Assessment  
Elevated Lp(a) is recognized as an important  risk factor for cardiovascular disease. Lp(a) will be 
collected for each participant at the times shown in the SoA (Section 1.3). 
8.1.2.  Secondary Efficacy Assessments  
The 2018 AHA/ACC Guideline on the management of blood cholesterol identified Lp(a) 
≥50 mg/dL (≥125  nmol/L) as risk enhancing . As a responder analysis, the proportions of 
participants achieving Lp(a) < 125 and <75 nmol/ L will be assessed . 
At times specified in the SoA, blood samples will be collected to measure changes in levels of 
these markers  
 ApoB  
 high-sensitivity C -reactive protein (hsCRP ) 
8.2. Safety Assessments  
Planned time points for all safety assessments are provided in the SoA.  
8.2.1.  Elect rocardiograms  
Single  12-lead ECG will be obtained as outlined in the SoA (see Section  1.3) using an ECG 
machine that automatically calculates the heart rate and measures pulse rate , QRS, QT, and QTc 
intervals. Refer to Section 7.1.2  for QTc withdrawal criteria and any additional QTc readings 
that may be necessary . 
8.2.2.  Clinical Safety Laboratory Tests  
● See Appendix 10.[ADDRESS_199256] of clinical laboratory tests to be performed and the 
SoA for the timing and frequency.  
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
39 ● The investigator must review the laboratory results , document this review, and 
report  any clinically relevant changes occurring during the study as an AE . The 
laboratory results must be retained with source documents unless a Source 
Documen t Agreement or comparable document cites an electronic location that 
accommodates the expected retention duration. Clinically significant abnormal 
laboratory findings are those which are not associated with the underlying disease, 
unless judged by [CONTACT_41411] ’s condition.  
● All laboratory tests with val ues considered clinically significantly abnormal 
during participation in the study  and deemed to be related to LY3819469 , in the 
opi[INVESTIGATOR_871] , or within [ADDRESS_199257] dose of study 
intervention should be repeated  until the values return to normal or baseline or are 
no longer considered clinically significant by [CONTACT_10982].  
○ If such values do not return to normal/baseline within a period of time judged 
reasonable by [CONTACT_093], the e tiology should be identified and the 
sponsor notified.  
○ All protocol -required laboratory assessments, as defined in Appendix 2  
(Section  10.2), mus t be conducted in accordance with the SoA , standard 
collection requirements , and laboratory manual . 
● If laboratory values from non -protocol -specified laboratory assessments 
performed at an investigator -designated local laboratory require a change in 
participant management or are considered clinically significant by [CONTACT_093] 
(for example , SAE or AE or dose modification), then  report the information as an 
AE.  
8.2.3.  Hepatic Safety  
Close hepatic monitoring  
Laboratory tests (Appendix 10.6), including ALT, AST, ALP, total bilirubin (TBL ), direct 
bilirubin (D. Bil ), gamma -glutamyl transferase (GGT ), and creatine kinase (CK), should be 
repeated within 48 to 72 hours to confirm the abnormality and to determine if it is increasing or 
decreasing, if one or more of these conditions occur:  
If a participant with baseline 
results of...  develops the following elevations:  
ALT or AST <1.5x ULN  ALT or AST  ≥3x ULN  
ALP <1.5x ULN  ALP ≥2x ULN  
TBL <1.5x ULN  TBL ≥2x ULN (except for patients with Gilbert’s syndrome)  
  
ALT or AST ≥1.5x ULN  ALT or AST ≥2x baseline  
ALP ≥1.5x ULN  ALP ≥2x baseline  
TBL ≥1.5x ULN  TBL ≥1.5x baseline (except for patients with Gilbert’s 
syndrome)  
Abbreviations: ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; 
TBL = total bilirubin; ULN= upper limit of normal.  
 
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
40 If the abnormality persists or worsens, clinical and laboratory monitoring, and evaluation for 
possible causes of abnormal liver tests should be initiated by [CONTACT_61520] -designated medical monitor. At a minimum, this eva luation should include physical 
examination and a thorough medical history, including symptoms, recent illnesses (for example, 
heart failure, systemic infection, hypotension, or seizures), recent travel, history of concomitant 
medications (including OTC ), herbal and dietary supplements, history of alcohol drinking and 
other substance abuse.  
Initially, monitoring of symptoms and hepatic biochemical tests should be done at a frequency of 
1 to 3 times weekly, based on the participant’s clinical condition and hepatic biochemical tests. 
Subsequently, the frequency of monitoring may be lowered to once every 1 to 2 weeks, if the 
participant’s clinical condition and lab results stabilize.  Monitoring of ALT, AST, ALP, and 
TBL should continue until levels normalize o r return to approximate baseline levels.  
Comprehensive hepatic evaluation  
A comprehensive evaluation should be performed to search for possible causes of liver injury if 
one or more of these conditions occur:  
If a participant with baseline 
results of...  develops the following elevations:  
ALT or AST <1.5x ULN  ALT or AST ≥3x ULN with hepatic signs/symptoms a, or  
ALT or AST ≥5x ULN  
ALP <1.5x ULN  ALP ≥3x ULN  
TBL <1.5x ULN  TBL ≥2x ULN (except for patients with Gilbert’s syndrome)  
  
ALT or AST ≥1.5x ULN  ALT  or AST ≥2x baseline with hepatic signs/symptoms a, or 
ALT or AST ≥3x baseline  
ALP ≥1.5x ULN  ALP ≥2x baseline  
TBL ≥1.5x ULN  TBL ≥2x baseline (except for patients with Gilbert’s syndrome)  
Abbreviations: ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; 
TBL = total bilirubin; ULN= upper limit of normal.  
a Hepatic signs/symptoms are severe fatigue, nausea, vomiting, right upper quadrant abdominal pain, fever, rash, 
and/or eosinophilia >5%.  
 
At a minimum, this evaluation should include physical examination and a thorough medical 
history, as outlined above, as well as tests for prothrombin time , international normalized ratio 
(PT-INR); tests for viral hepatitis A, B, C, or E; tests for autoimmune hepatitis; and an 
abdominal imaging study (for example, ultrasound or computerized tomography [CT] scan).  
Based on the patient’s history and initial results, further testing should be considered in 
consultation with the Lilly -designated medical monitor, including te sts for hepatitis D virus 
(HDV), cytomegalovirus (CMV), Epstein -Barr virus (EBV), acetaminophen levels, 
acetaminophen protein adducts, urine toxicology screen, Wilson’s disease, blood alcohol levels, 
urinary ethyl glucuronide, and blood phosphatidylethanol . Based on the circumstances and the 
investigator’s assessment of the participant’s clinical condition, the investigator should consider 
referring the participant for a hepatologist or gastroenterologist consultation, magnetic resonance 
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
41 cholangiopancreatog raphy (MRCP), endoscopic retrograde cholangiopancreatography (ERCP), 
cardiac echocardiogram, or a liver biopsy.  
Additional hepatic data collection (hepatic safety CRF) in study participants who have 
abnormal liver tests during the study  
Additional hepati c safety data collection in hepatic safety CRF should be performed in study 
participants who meet 1 or more of the following 5 conditions:  
1. Elevation of serum ALT to ≥5x ULN on 2 or more consecutive blood tests (if baseline 
ALT <1.5x ULN)  
➢ In participants with baseline ALT ≥1.5x ULN, the threshold is ALT ≥3x baseline 
on 2 or more consecutive tests  
2. Elevated TBL to ≥ 2x ULN (if baseline TBL <1.5x ULN) (except for cases of known 
Gilbert ’s syndrome)  
➢ In participants with baseline TBL ≥1.5x ULN,  the threshold should be TBL ≥2x 
baseline  
3. Elevation of serum ALP to ≥2x ULN on 2 or more consecutive blood tests (if baseline 
ALP <1.5x ULN)  
➢ In participants with baseline ALP ≥1.5x ULN, the threshold is ALP ≥2x baseline 
on 2 or more consecutive blood tests  
4. Hepatic event considered to be a n SAE  
5. Discontinuation of study drug due to a hepatic event  
Note: the interval between the [ADDRESS_199258] 2 days.  
8.2.4.  Hepatitis B Testing and Monitoring  
As specified in the SoA (Section 1.3), initial testing for HBV infection includes H bsAg and 
hepatitis B core antibody (H bcAb).  
● If HbsAg is positive, the participant is excluded.  
● If HbsAg is negative and H bcAb is negative, the participant is not excluded.  
● If HbsAg is negative and H bcAb is positive, further testing for HBV DNA is 
required.  
○ If the screening HBV DNA is positive, the participant is excluded.  
○ If the screening HBV DNA is ne gative, the participant is not excluded. Repeat 
testing for HBV DNA is required at least every 3 months during the study.  
Management of enrolled participants with detectable HBV DNA during the study  
If HBV DNA is detected, study intervention will be tempor arily withheld or permanently 
discontinued, as described in Section 7.1, and the participant should receive appropriate follow -
up medical care . 
8.2.5.  Hepatitis C Testing  
As specified in the SoA (Section 1.3), initial testing for HCV infection includes testing for 
anti-HCV.  
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
42 ● If anti -HCV is positiv e, a test for circulating HCV RNA is required.  
● If HCV RNA test is negative, the participant is not excluded.  
● If HCV RNA test is positive, the participant is excluded.  
Participants who have had HCV infection and have been successfully treated, defined as a 
sustained virologic response (HCV RNA by [CONTACT_170271] 24 weeks following 
treatment completion) , are not excluded on the basis of HCV as long as HCV RNA test is 
negative at screening.  
If HCV RNA is detected during the study, the study inte rvention will be discontinued 
(Section  7.1), and the participant should receive appropriate follow -up medical care.  
8.2.6.  Injection Site Reactions  
Symptoms and signs of a local injection site reaction (ISR) may include erythema, induration, 
pain, pruritus, and edema.  
If an ISR is reported by a participant or site staff, the ISR CRF will be used to capture additional 
informat ion about this reaction (for example, injection -site pain, degree and area of erythema, 
induration, pruritis and edema).  
8.2.7.  Hypersensitivity Reactions  
Many drugs, including oral agents and biologic agents, carry the risk of systemic hypersensitivity 
reactions . If such a reaction occurs, additional data should be provided to the sponsor in the 
designated CRFs.  
Sites should have appropriately trained medical staff and appropriate medical equipment 
available when study participants are receiving study interventio n. It is recommended that 
participants who experience a systemic hypersensitivity reaction be treated per national and 
international guidelines.  
In the case of a suspected systemic hypersensitivity event, additional blood samples should be 
collected as des cribed in Appendix 10.2.[ADDRESS_199259] Complaints  
The definitions of the following events can be found in Appendix 3:  
 AEs 
 SAEs  
 Product complaints (PCs)  
These events will be reported by [CONTACT_2299] (or, when appropriate, by a caregiver, surrogate, 
or the participant ’s legally authori zed representative).  
The investigator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the se definition s and remain responsible for following up events that 
are serious, considered related to the study intervention or study procedures, or that caused the 
participant to discontinue the study intervention  or study (see Section 7). 
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
43 Care will be taken not to introduce bias when detecting events . Open -ended and non -leading 
verbal questioning of the participant is the preferred method to inquire about event occurrences.  
After the initial report, the investigator is required to proactively follow each participant at 
subsequent visits/contacts. All SAEs will be followed until resolution, stabilization, the event is 
otherwise explained, or the participant is lost to follow -up (as defined in Section 7.3). For PCs, 
the investigator is responsible for ensuring that follow -up includes any supplemental 
investigations as indi cated to elucidate the nature and/or causality.  Further information on 
follow -up procedures is provided in Appendix 10.3.  
8.3.1.  Timing and Mechanism for Collecting Events  
This table describes the timing, deadlines, and mechanism for collecting events.  
Event  Collection 
Start  Collection 
Stop  Timing  for Reporting 
to Sponsor or 
Designee  Mechanism for 
Reporting  Back -up 
Method of 
Reporting  
Adverse Event  
AE Signing of 
the ICF  Participation 
in study has 
ended  As soon as possible 
upon site awareness  AE CRF  N/A 
AE – related to 
prescreening 
study procedure  Signing of 
the 
prescreening  
ICF Signing of 
the ICF  As soon as possible 
upon site awareness  AE CRF  N/A 
Serious Adverse Event  
SAE and SAE 
updates – prior 
to start of study 
intervention and 
deemed 
reasonably 
possibly related 
to study 
procedures  Signing of 
the ICF  Start of 
intervention  Within 24 hours of 
awareness  SAE CRF  SAE paper 
form  
SAE  and SAE 
updates – after 
start of study 
intervention  Start of 
intervention  Participation 
in study has 
ended  Within 24 hours of 
awareness  SAE CRF  SAE paper 
form  
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
44 Event  Collection 
Start  Collection 
Stop  Timing  for Reporting 
to Sponsor or 
Designee  Mechanism for 
Reporting  Back -up 
Method of 
Reporting  
SAEa – after 
participant’s 
study 
participation has 
ended and the 
investigator 
becomes aware  After 
participant’s 
study 
participation 
has ended  N/A Promptly  SAE paper form  N/A 
Pregnancy  
Pregnancy in 
female 
participants and 
female partners 
of male 
participants  After the 
start of study 
intervention  Participation 
in study has 
ended  Within 24 hours (see 
Section 8.3.2 ) Pregnancy paper 
form  Pregnancy 
paper form  
Product Complaints  
PC associated 
with an SAE  or 
might have led 
to an SAE  Start of 
study 
intervention  End of study 
intervention  Within 24 hours of 
awareness  PC form  N/A 
PC not 
associated with 
an SAE  Start of 
study 
intervention  End of study 
intervention  Within 1 business day 
of awareness  PC form  N/A 
Updated PC 
information  — — As soon as possible 
upon site awareness  Originally 
completed P C form 
with all changes 
signed and dated by 
[CONTACT_093]  N/A 
PC, if 
investigator 
becomes aware  Participation 
in study has 
ended  N/A Promptly  PC form   
Abbreviations: AE = adverse event; CRF = case report form; ICF = informed consent form; N/A = not applicable; 
PC = product complaint; SAE = serious adverse event.  
a SAEs should not be reported unless the investigator deems them to be possibly related to study treatment or study 
participation.  
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
45 8.3.2.  Pregnancy  
Collection of pregnancy information  
Male participants with partners who become pregnant  
● The investigator will attempt to collect pregnancy information on any male 
participant’s female partner who becomes pregnant while the male participant is 
in this study. This applies only to male participants who receive  study 
intervention . 
● After learning of a pregnancy in the female partner of a study participant, the 
investigator will  
o obtain a consent  to release information  from the pregnant female partner 
directly, and 
o within [ADDRESS_199260] pregnancy information 
on the appropriate form and submit it to the sponsor .  
The female partner will also be followed to determine the outcome of the 
pregnancy. Information on the status of the mother and child will be forwarded to 
the sponsor. Ge nerally, the follow -up will be no longer than 6 to 8  weeks 
following the estimated delivery date. Any termination of the pregnancy will be 
reported regardless of  gestational age,  fetal status (presence or absence of 
anomalies) or indication for the procedu re. 
Female participants who become pregnant  
● The investigator will collect pregnancy information on any female participant 
who becomes pregnant while participating in this study. The initial i nformation 
will be recorded on the appropriate form and submitted to the sponsor within 
24 hours  of learning of a participant ’s pregnancy.  
● The participant will be followed to determine the outcome of the pregnancy. The 
investigator will collect follow -up information on the participant and the neonate 
and the information will be forwarded to the sponsor. Generally, follow -up will 
not be required for longer than 6 to 8 weeks beyond the estimated delivery date. 
Any termination of pregnancy will be r eported , regardless of gestational age,  fetal 
status (presence or absence of anomalies) or indication for the procedure.  
● While pregnancy itself is not considered to be an AE or SAE, any pregnancy 
complication or elective termination of a pregnancy for me dical reasons will be 
reported as an AE or SAE.  
● A spontaneous abortion (occurring at <2 0 weeks gestational age) or still birth 
(occurring at ≥20 weeks gestational age) is always considered to be an SAE and 
will be reported as such.  
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
46 ● Any poststudy pregnancy -related SAE considered reasonably related to the study 
intervention by [CONTACT_170272]  8.3.1 . While the investigator is not obligated to actively seek this 
information in former study participants, he or she may learn of an SAE through 
spontaneous reporting.  
● Any female participant who becomes pregnant while participating in the study 
will discontinue study intervention . If the participant is discontinued from the 
study, follow the standard discontinuation process and continue directly to the 
follow -up phase. The follow -up on the pregnancy outcome should conti nue 
independent of intervention or study discontinuation . 
8.3.3.  Major Adverse Cardiovascular Events  
Nonfatal cardiovascular AEs will be adjudicated by a committee of physicians external to Lilly 
with cardiology expertise. This committee will be blinded to treatm ent assignment.  
The nonfatal cardiovascular AEs to be adjudicated include  
 myocardial infarction  
 hospi[INVESTIGATOR_10929]  
 hospi[INVESTIGATOR_19934]  
 coronary interventions, such as coronary artery by[CONTACT_170273], and  
 cerebrovascular events, including cerebrovascular accident (stroke) and transient 
ischemic attack.  
8.4. Pharmacokinetics  
 At the visits and times specified in the SoA (Section 1.3), blood samples will be collected 
to determine the LY3819469  plasma concentrations.  
 Participants may need to return to the clinical site for PK -specific visits to provide 
postdose PK samples dependent on the time window of PK sampling.  
 Instructions for the collection and handling of blood samples will be provided by [CONTACT_103]. Sampling times for PK evaluation are provided as a guidance and should be 
adhered to as closely as possible. The actual date and time (24 -hour clock time) of each 
sample collection will be recorded.  
 Drug concentration information that would  unblind the study will not be reported to 
investigative sites or blinded personnel . 
 A validated assay will be used to determine plasma LY3819469  concentr ations from the 
blood samples collected. The blood samples will be analyzed at a laboratory approved by 
[CONTACT_456]. The samples will be retained for a maximum of [ADDRESS_199261] study 
visit for the study. During this time, any samples remaining afte r the bioanalysis is 
complete may be used for exploratory analyses, such as metabolism, protein binding, or 
bioanalytical method development or validation work.  
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
47 8.5. Pharmacodynamics  
Samples to evaluate the PD properties of LY 3819469  are included in the efficacy measures and 
not applicable here.  
8.6. Genetics  
An optional  blood sample for DNA isolation will be collected from participants.  
See Appendix  10.5 for information regarding genetic research and Appendix 10.1.12  for details 
about s ample retention and custody . 
8.7. Biomarkers  
Serum and plasma samples will be collected and used for exploratory biomarker research, where 
local regulations allow. See Clinical Laboratory Tests and the SoA for sample collection 
information.  
Samples will be used for research on the drug target, disease process, variable response to 
LY3819469 , pathways associated with lipid metabolism, mechanism of action of LY3819469 , 
and/or research method, or for validating diagnostic tools or assay(s) relat ed to lipid metabolism 
or other relevant disease states.  
Samples may be used for research to develop methods, assays, prognostics , and/or  companion 
diagnostics related to the intervention target, disease state, pathways associated with disease, 
and/or the mechanism of action of the study intervention . 
Sample retention  is described in  Section  10.1.12 . 
8.8. Immunogenicity Assessments  
At the visits and times specified in the SoA (Section 1.3), venous blood samples will be collected 
(if local regulations and ethical review boards allow) and stored for potential future analysis to 
determine antibody production against LY3819469. Antibodies may be further characterized for 
their ability to neutralize the activity of LY3819469. To interpret the results of immunogenicity, 
a venous bloo d sample will be collected at the same time points to determine the plasma 
concentrations of LY3819469. Samples for immunogenicity should be taken predose when 
applicable and possible.  
In the event of drug hypersensitivity reactions (immediate or nonimmedi ate), additional samples 
will be collected as described in Section 10.2.[ADDRESS_199262] participa nt visit  per Section 
10.1.12 , or for a shorter period if local regulations and ethical review boards allow, at a facility 
selected by [CONTACT_456]. T he duration allows the sponsor to respond to future regulatory requests 
related to the LY3819469. Any samples remaining after 15 years will be destroyed.  
8.9. Health Economic s 
Health economics or medical resource utilization and health economics parameters are not 
evaluated in this study.  
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
48 9. Statistical Considerations  
9.1. Statistical Hypotheses  
The study hypothesis for the primary objective is that SC injection of LY3819469  16 mg, 96 mg, 
or 400 mg is superior to placebo in percent change from baseline in time -averaged  Lp(a)  over 
Days 60 -180 in participants with elevated Lp(a) . 
9.1.1.  Multiplicity Adjustment  
Treatment comparisons will be performed for the primary objective at the full significance level 
of 0.05. No multiplicity adjustments will be made for the analysis of secon dary and exploratory 
objectives.  
9.2. Analyses  Sets 
This table defines the analysis population and data sets for the purposes of analysis . 
Population  Description  
Screened  All participants  who sign  the ICF. 
Randomized  All participants who are randomly assigned  to a treatment arm . 
Full Analysis Set (FAS)  All data for patients who are randomized, take at least one dose of study 
medication, and  are not discontinued due to inadvertent enrollment . 
Participants will be analyzed according to the treatment they were assigned.  
Abbreviation: ICF = informed consent form.  
9.3. Statistical Analyses  
9.3.1.  General Considerations  
Statistical analysis of this study will be the responsibility of Lilly or its designee.  
Any change to the data analysis methods described in the protocol will  require an amendment 
only if it changes a principal feature of the protocol. Any other change to the data analysis 
methods described in the protocol, and the justification for making the change, will be described 
in the statistical analysis plan ( SAP) or the clinical study report (CSR). Additional exploratory 
analyses of the data will be conducted as deemed appropriate.  
Unless otherwise noted, all tests will be conducted at a 2 -sided alpha level of 0.05, and 
confidence intervals will be calculated at 9 5%, [ADDRESS_199263] dose of intervention, unless otherwise specified.  
Handling of missing, unused, and spurious data are addressed prospectively in the overall 
statistical methods described in the protocol and in the SAP, where appropriate. Adjustments to 
the planned analyses are described in the final CSR.  
9.3.2.  Primary Endpoint (s)/Estimand(s)  Analysis  
The primary efficacy assessment, guid ed by [CONTACT_941]  “treatment -regimen” estimand , which represents 
the efficacy regardless of treatment discontinuation , will be conducted using the  Full Analysis 
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
49 Set (FAS). The missing values for Lp(a) measurements at each time point (up to 6  months) will 
be handl ed by [CONTACT_170274]  (MAR).  Then, the 
time-averaged Lp(a) for each patient will be calculated based on the observed and imputed data.  
Specifically, the  AUC for log -transformed Lp(a)  over Day 60 to Day 180 will  be calculated 
using the trapezoidal rule  according to the scheduled time, and the time -averaged log[Lp(a)] is 
the AUC for log[Lp(a)] divided by 120 (days). The time -averaged Lp(a) is calculated as the 
exponentiation of the time -averaged log[Lp(a)].  
The ch ange in the time -averaged log[Lp(a)] from baseline will be analyzed using an analysis of 
covariance (ANCOVA) mode l including treatment, high risk of cardiovascular event (yes/no), 
and baseline log[Lp(a) ] as a covariate. For the primary analysis up to Day 180, the two 
LY3819469 treatment groups assigned t o [ADDRESS_199264] 180 days . The percent 
change for the time -averaged Lp(a) will be calculated and reported  by [CONTACT_170275]-averaged log[Lp(a)]  in the above model  and the 
corresponding standard error will be calculated using the delta -method.  
Additional covariates may be added, and this analysis will be detail ed in the SAP.  
9.3.3.  Secondary Endpoint (s)/Estimand(s)  Analysis  
Secondary endpoints are listed in Section  3. 
The efficacy analyses for the secondary endpoints will use the FAS described in Section  
9.3.1 .and may also pool the two LY 3819469 400-mg treatment groups, where appropriate . 
Analyses  for percent change from baseline in time -averaged Lp(a) over Days 240 -360 will be 
conducted in a manner similar to the primary efficacy analysis  discussed in Section 9.3.2 .  
The continuous clinical measures , including Lp(a),  ApoB , and hsCRP , may be log transformed 
before statistical analyses, if deemed necessary. Analyses for change from baseline in each log -
transformed parameter  at Days 60, 180, 240, 360, and 540  will be conducted using mixed  model  
for repeated measures (MMRM ). The percent change from baseline will be calculated and 
reported  by [CONTACT_170276].  
Analyses for percentages of participants reaching Lp(a) <125 nmol/L  and <75 nmol/L at Day 60, 
180, 240, 360, and 540  will be conducted using logistic regression model ing. 
In these models, additional covariates may be added, if deemed necessary. The details will be 
provided in the SAP.  
9.3.4.  Exploratory Endpoint (s) Analysis  
Details of analyses for the exploratory objectives will be pro vided in the SAP.  
9.3.5.  Safety Analyse s 
Safety assessments will be guided by [CONTACT_170277] 3819469  doses with 
placebo irrespective of adherence to intervention. Thus, safety analyses will be conducted using 
the FAS. Safety assessments may als o pool the 2 LY3819469 400-mg treatment groups, where 
appropriate.  
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
50 AEs will be coded from the actual term using the Medical Dictionary for Regulatory Activities 
(MedDRA) and reported with preferred terms and system organ class. Selected notable AEs of 
interest may be reported using high -level terms or Standardized MedDRA Queries.  
Summary statistics will be provided for incidence of  
 treatment -emergent adverse events ( TEAEs ) 
 SAEs  
 study discontinuation due to AEs 
 intervention discontinuation due to AEs 
 deaths,  and 
 other cardiovascular endpoints.  
Counts and proportions of participants experiencing AEs will be reported for each treatment 
group, and Fisher’s exact test will be used to compare the treatment groups.  
[IP_ADDRESS].  Laboratory Measures, Vital Signs, and Electrocardiograms  
Laboratory measures and vital signs will be summarized for each scheduled visit by  
 actual measures at baseline and postbaseline  
 change from baseline to postbaseline, or  
 percent change from baseline to postbaseline.  
The laboratory measure s may be log -transformed before statistical analyses, if deemed 
necessary. Laboratory measures may also pool the 2 LY3819469 400-mg treatment groups, 
where appropriate. Continuous variables , as well as the change from baseline for these variables 
or other appropriate transformed variables, will be analyzed by [CONTACT_170278]  9.3.1 . 
The percentages of participants with treatment -emergent abnormal, high, or low measures, 
including laboratory and vital parameters, will be summarized and compared between treatment 
groups using Fisher’s exact test.  
The analysis details will be provided in the SAP.  
9.3.6.  Pharmacokinetic and Pharmac odynamic Analyses  
LY3819469 concentration data will be summarized and analyzed using a population PK 
approach via nonlinear mixed -effects modeling.  
The relationships between LY3819469 dose and concentration and selected efficacy and safety 
endpoints may b e characterized. Addi tionally, the impact of intrinsic and extrinsic factors, such 
as age, weight, gender, and liver function on PK and PD parameters, may be examined as 
needed.  
If anti -drug antibody (ADA) titers are detected from immunogenicity testing, t hen the impact of 
immunogenicity titers on LY3819469 PK or any relevant efficacy parameters may also be 
examined. Additional analyses may be conducted if they are deemed appropriate.  
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
51 9.3.7.  Immunogenicity Assessments  
If data from validated immunogenicity assays are available, treatment -emergent anti-drug 
antibodies (TE-ADAs ) may be assessed.  
TE-ADAs are defined as participants  
 with a 2 -fold (1 dilution) increase in titer than the minimum required dilution if no ADAs 
were detected at baseline (treatment -induced ADA), or  
 with a 4 -fold (2 dilutions) increase in titer compared with baseline if ADAs were detected 
at baseline (treatment -boosted ADA).  
The frequency and percentage of participants with preexisting ADA and who are TE -ADA 
positive (TE -ADA+) to LY3819469  will be tabulated.  
The distribution of titers and frequency of neutralizing antibodies (if assessed) for the TE -ADA+ 
participants may also be tabulated.  
The relationship between the presence of antibodies and PK parameters, efficacy response , or 
safety  to LY3819469  may also be assessed. Additional details may be provided in the SAP.  
9.3.8.  Subgroup Analyses  
Subgroup analyses of important factors, such as baseline Lp(a) level,  and other factors to be 
specified in the  SAP, are planned for the key outcomes.  The models used for these analyses will 
vary depending on the subgroups and the outcome. Other exploratory subgroup analyses may be 
performed as deemed appropriate.  Details of the modeling will be provided in the SAP.  
9.4. Interim Analys is 
There may be up to [ADDRESS_199265]  10% of the participants complete 
Day 180  at Visit 7 or discontinue the study. The interim will be for the purpose of internal 
planning and decision -making and may assess safety, PK,  and/or efficacy measures . Additional 
details related to statistical methods will be described in the SAP.  If this happens, an  assessment 
committee (AC) will be formed to review the interim analyses in an unblinded manner. The 
details regarding the number of participants and type of analysis will be provided in the AC 
charter  and in the unblinding plan . Information that may unblind the study during the analyses 
will not be reported to study sites or blinded study team members before the study has be en 
unblinded. Study sites will receive information about interim results only if deemed necessary 
for the safety of the participants.  The study will not be stopped based on the efficacy of 
LY3819469 versus placebo. Therefore, there will be no inflation of the type [ADDRESS_199266] completed Day 180 (Visit 7 ). After primary analysis,  additional efficacy and 
safety assessment may occur when all participants have completed 240 days  (Visit  9) and 10% of 
participants have completed 360 days  (Visit 1 1) of the treatment. The final database lock and 
final data analysis will occur when all randomized participants have completed the study. 
Participants and investigators will remain blinded until the completion of the study.   
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
52 The addition of an interim analysis can be determin ed at any time during the study and will not 
result in a protocol amendment.  The SAP will describe the interim analys es in greater detail.  
9.5. Sample Size Determination  
Approximately 2 54 participants will be randomly assigned in a 1:2:2:2 :2 ratio to LY3819469 
16 mg 2 doses : 96 mg 2 doses : 400 mg 2 doses : 400 mg 1 dose  and placebo  1 dose :placebo  
2 doses. Assuming a 15% dropout rate, this results in approximately [ADDRESS_199267] deviation of 20%, and a 2 -sided alpha level of 0.05, the completers for each 
treatment arm will provide >99% power to detect a treatment difference of 70% reduction  for the 
primary endpoint  of LY3819469 versus  placebo . The sample size w as determined appropriate to 
provide a sufficient amount of safety data.  
 
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
53 10. Supporting Documentation and Operational Considerations  
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations  
10.1.1.  Regulatory and Ethical Considerations  
● This study will be conducted in accordance with the protocol and with the 
following:  
○ Consensus ethical principles derived from international guidelines including 
the Declaration of Helsinki and Council for International Organizations of 
Medical Sciences (CIOM S) International Ethical Guidelines  
○ Applicable International Council for Harmonisation (ICH) Good Clinical 
Practice (GCP) Guidelines  
○ Applicable laws and regulations  
● The protocol, protocol amendments, ICF, IB, and other relevant documents ( for 
example , advertisements) must be submitted to an Institutional Review 
Board/ Independent Ethics Committee ( IRB/IEC ) by [CONTACT_97277]/IEC  before the study is initiated.  
● Any amendments to the protocol will require IRB/IEC ap proval before 
implementation of changes made to the study design, except for changes 
necessary to eliminate an immediate hazard to study participants.  
● Protocols and any substantial amendments to the protocol will require health 
authority approval prior t o initiation except for changes necessary to eliminate an 
immediate hazard to study participants . 
● The investigator will be responsible for the following:  
○ Providing written summaries of the status of the study to the IRB/IEC 
annually or more frequently in accordance with the requirements, policies, and 
procedures established by [CONTACT_1201]/IEC  
○ Notifying the IRB/IEC of SAEs  or other significant safety findings as required 
by [CONTACT_1744]/IEC procedures  
○ Providing oversight of study conduct for participants under their responsibility 
and adherence to requirements of 21 C ode of Federal Regulations (C FR), ICH 
guidelines, the IRB/IEC, European regulation 536/2014 for clinical studies (if 
applicable), and all other applicable local regulations  
○ Reporting to the sponsor or designee significant issues related to participant 
safety, participant rights, or data integrity  
● Investigator sites are compensated for participation in the study  as detailed in the 
clinical trial agreement . 
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
54 10.1.2.  Fina ncial Disclosure  
Investigators and sub -investigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropri ate regulatory authorities. Investigators are 
responsible for providing information on financial interests during the course of the study and for 
1 year after completion of the study.  
10.1.3.  Informed Consent Process  
● The investigator or the investigato r’s representative will explain the nature of the 
study , including the risks and benefits,  to the participant and answer all  questions 
regarding the study.  
● Participants must be informed that their participation is voluntary. Participants 
will be required to sign a statement of informed consent that meets the 
requirements of 21 CFR 50, local regulations, ICH guidelines, privacy and data 
protection requirements , where applicable, and the I RB/IEC or study center.  
● The medical record must include a statement that written informed consent was 
obtained before the participant was enter ed in the study and the date the written 
consent was obtained. The authorized pers on obtaining the informed consent must 
also sign the ICF.  
● Participants must be reconsented to the most current version of the ICF(s) during 
their participation in the study.  
● A copy of the ICF(s) must be provided to the participant and is kept on file . 
Participants who are rescreened are required to sign a new ICF.  
10.1.4.  Data Protection  
● Participants will be assigned a unique identifier by [CONTACT_456]. Any participant 
records , datasets  or tissue samples  that are transferred to the sponsor will conta in 
the identifier only; participant names or any information which would make the 
participant identi fiable will not be transferred.  
● The participant must be informed that the participant’s  personal study -related data 
will be used by [CONTACT_61526]. The 
level of disclosure must also b e explained to the participant  who will be required 
to give consent for their data to be used as described in the informed consent .  
● The participant must be informed that their medical records may be examined by 
[CONTACT_103083], by [CONTACT_6667]/IEC members, and by [CONTACT_9326].  
● The sponsor has processes in place to ensure da ta protection, information security , 
and data integrity. These processes include appropriate contingency plan(s) for 
appropriate and timely response in the event of a data security breach.  
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
55 10.1.5.  Committees Structure  
[IP_ADDRESS].  External Clinical Endpoints Committee  
An independent clinical endpoint committee, external to Lilly, will be formed to adjudicate 
major adverse cardiac events (MACE ) and deaths. This committee will be blinded to treatment 
assignment.  
10.1.6.  Dissemination of Clinical Study Data  
Reports  
The spo nsor will disclose a summary of study information, including tabular study results, on 
publicly available websites where required by [CONTACT_51967].  
The summary of results will be posted within the time frame specified by [CONTACT_51967].  
If the study remains ongoing in some countries and a statistical analysis of an incomplete data set 
would result in analyses lacking scientific rigor (for example, underpowered) or compromise the 
integrity of the overall analyses (for example, trial not ye t unblinded), the summary of results 
will be submitted within [ADDRESS_199268], see the instructions provided at www.vivli.org . 
10.1.7.  Data Quality Assurance  
● All participant data relating to the study will be recorded on printed or electronic 
CRF s unless transmitted to the sponsor or designee electro nically ( for example , 
laboratory data). The investigator is responsible for verifying that data entries are 
accurate and correct by [CONTACT_1189].  
● The investigator must maintain accurate documentation (source data) that 
supports the information entered in  the CRF.  
● The investigator must permit study -related monitoring, audits, IRB/IEC review, 
and regulatory agency inspections and provide direct a ccess to source data 
documents.  
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
56 ● Quality tolerance limits (QTLs) will be prede fined to identify systematic issues 
that can impact participant safety and/or reliability of study results. These 
predefined parameters will be monitored during the study and important 
excursions  from the QTLs and remedial actions taken will be summarized in the 
CSR . 
● Monitoring details describing strategy ( for example , risk -based initiatives in 
operations and quality such as risk management and mitigation strategies and 
analytical risk -based monitori ng), methods, responsibilities and requirements, 
including handling of noncompliance issues and monitoring techniques , are 
provided in the Monitoring Plan . 
● The sponsor or designee is responsible for the data management of this study 
includin g quality checking of the data.  
● The sponsor assumes accounta bility for actions delegated to other individuals ( for 
example , contract research organizations ). 
● Study monitors will perform ongoing source data verification to confirm that data 
transcribed  into the CRF by [CONTACT_1191], comple te, and 
verifiable from source documents; that the safety and rights of participants are 
being protected; and that the study is being conducted in accordance with the 
currently approved protocol and any other study agreements, ICH GCP, and all 
applicable r egulatory requirements.  
● Records and documents, including signed ICFs, pertaining to the conduct of this 
study must be retained by [CONTACT_170279] (CTA)  unless local regulations or institutiona l policies 
require a longer retention period. No records may be destroyed during the 
retention period without the written approval of the sponsor. No records may be 
transferred to another location or party without written notification to the sponsor . 
● In addition, sponsor  or its representatives will periodically check a sample of the 
participant  data recorded against source documents at the study site. The study 
may be audited by [CONTACT_81284], and/or regulatory agencies at 
any time. Inves tigators will be given notice before an audit occurs.  
Data Capture System  
The investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness 
of the data reported to the sponsor.   
An electronic data capture system (EDC) will be used in this study for the collection of CRF 
data. The investigator maintains a separate source for the data entered by [CONTACT_82413] -provided EDC system. The investigator is responsible for the 
identification of any data to be considered source and for the confirmation that data reported are 
accurate and complete by [CONTACT_11003] . 
Data collected via the sponsor -provided data capture system s will be  stored at third parties . The 
investigator will have continuou s access to the data during the stu dy and until decommissioning 
Approved on [ADDRESS_199269] data, will be stored electronically in 
the central vendor’s database system and reports  will be provided to the investigator for review 
and retention. Data will subsequently be transferred from the central vendor to the sponsor data 
warehouse.  
Data from complaint forms submitted to the sponsor will be encoded and stored in the global 
product complaint management system.  
 
10.1.8.  Source Documents  
● Source documents provide evidence for the existence of the participant and 
substantiate the integrity of the data collected. Source documents are filed at the 
investigator’s site.  
● Data reported  on or entered in the CRF and are transcribed from source 
documents must be consistent with the source documents or the discrepancies 
must be explained. The investigator may need to request previous medical records 
or transfer records, depending on the study. Also, current medical records must be 
available.  
● Definition of what constitutes source data can be found in  Section 10.1.[ADDRESS_199270] participant to enter screening.  
Study or Site Termination  
The sponsor or sponsor’s designee reserves the right to close the study site or terminate the study 
at any time for any reason at the sole discretion of the spo nsor. Study sites will be closed upon 
study completion. A study site is considered closed when all required documents and study 
supplies have been collected and a study -site closure visit has been performed.  
The investigator may initiate study -site closure  at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.  
Reasons for the early closure of a study site by [CONTACT_11004]:  
For study termination:  
● Discontinuation of further study intervention development  
For site termination:  
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
58 ● Failure of the investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor ’s procedures, or GCP guidelines  
● Inadequate recruitment (evaluated after a reasonable amount of time)  of 
participants by [CONTACT_093]  
● Total number of participants included earlier than expected  
If the study is prematurely terminated or suspended, the sponsor shall promptly inform th e 
investigators, the IECs/IRBs, the regulatory authorities, and any contract research organization(s) 
used in the study of the reason for termination or suspension, as specified by [CONTACT_11005]. The investigator shall promptly inf orm the participant  and should assure 
appropriate participant  therapy and/or follow -up. 
10.1.10.  Publication Policy  
In accordance with the sponsor’s publication policy , the results of this study will be submitted 
for publication by a peer -reviewed journal.  
10.1.11.  Investigator Information  
Researchers with appropriate education, training, and experience, as determined by [CONTACT_456], 
will participate as investigators in this clinical trial . 
10.1.12.  Sample Retention  
Sample retention enables use of new technologies, response t o regulatory questions, and 
investigation of variable response that may not be observed until later in the development of  
LY3819469  or after  LY3819469  become(s) commercially available.  
 
Sample Type  Custodian  Retention Period After Last 
Participant  Visita 
Exploratory Biomarker  Samples  Sponsor or Designee  7 years  
PK Sponsor or Designee  1 years  
Genetics  Sponsor or Designee  7 years  
Immunogenicity  Sponsor or Designee  15 years  
Abbreviation: PK = pharmacokinetic.  
a Retention periods may differ locally.  
  
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
59 10.2. Appendix 2: Clinical Laboratory Tests  
● The tests detailed in the table below will be performed as noted in the table below . 
● Local laboratory results are only required in the event that the central laboratory 
results are not available in time f or either study intervention administration and/or 
response evaluation. If a local sample is required, it is important that the sample 
for central analysis is obtained at the same time. Additionally, if the local 
laboratory results are used to make either a study intervention decision or 
response evaluation, the results must be recorded.  
● In circumstances where the sponsor approves local laboratory testing in lieu of 
central laboratory testing (in the table below), the local laboratory must be 
qualified in accordance with applicable local regulations.  
● Protocol -specific requirements for inclusion or exclusion of participants are 
detailed in Section 5 of the protocol.  
● Additional tests may be performed at any time during the study as determined 
necessary by [CONTACT_11006].  
● Investigators must document their review of the laboratory safety results.  
Laboratory results  that could unblind the study will not be reported to investigative sites or other 
blinded personnel . 
Clinical Laboratory Tests   Comments  
Hematology  Assayed by [CONTACT_11007] -designated laboratory . 
Hemoglobin    
Hematocrit    
Erythrocyte count (RBCs)    
Mean cell volume    
Mean cell hemoglobin    
Mean cell hemoglobin concentration    
Absolute neutrophil count ( calculation)    
Leukocytes (WBCs)    
Differential    
Percent and/or absolutes count of:    
   Neutrophils, segmented    
   Bands    
   Lymphocytes    
   Monocytes    
   Eosinophils    
   Basophils    
Platelets    
Cell morphology (RBCs and WBCs)    
    
Approved on [ADDRESS_199271]    
GGT    
BUN    
Creatinine    
CK   
Uric acid    
Total protein    
Albumin    
Calcium    
Phosphorus    
Glucose    
    
Lipid Panel  Assayed by [CONTACT_11007] -designated laboratory.  
HDL -C  
LDL -C Generated by [CONTACT_11007] -designated laboratory.  
If triglycerides are >400;  direct  LDL will be 
measured.  
VLDL -C Generated by [CONTACT_11007] -designated laboratory.  
Cholesterol   
Triglycerides   
    
Urinalysis  Assayed by [CONTACT_11007] -designated laboratory . 
Specific gravity    
pH   
Protein    
Glucose    
Ketones    
Bilirubin    
Urobilinogen    
Blood    
Nitrite    
Urine leukocyte esterase    
Microscopic examination of sediment    
    
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
61 Clinical Laboratory Tests   Comments  
Hormones (female)    
Serum pregnancy  Assayed by [CONTACT_11007] -designated laboratory.  
FSH  Assayed by [CONTACT_11007] -designated laboratory.  
    
Calculations  Generated by [CONTACT_11007] -designated laboratory.  
eGFR (CKD -EPI)    
UACR   
    
TB, HIV, and Hepatitis Serology  Assayed by [CONTACT_11007] -designated laboratory . 
HIV testing   
HCV testing:   
   HCV antibody   
   HCV RNA   
HBV testing:   
   HBV DNA  Performed only for participants who test positive 
for H bcAb.  
   HbcAb    
   HbsAg    
   HbsAb   
    
Pharmacokinetic Samples  Assayed by [CONTACT_11007] -designated laboratory.   
LY3819469  concentration  Results will not be provided to the investigative 
sites.  
  
Immunogenicity  (ADA) samples  Assayed by [CONTACT_11007] -designated laboratory.  
Results will not be provided to the investigative 
sites.  
Anti-LY3819469  antibodies   
  
Additional Testing  Assayed by [CONTACT_11007] -designated laboratory.  
Lp(a)  Results will be provided to the investigative sites  
during prescreening or screening . Results will not 
be provided to the investigative sites  after 
randomization . 
ApoB  Results will not be provided to the investigative 
sites.  
hsCRP  Results will be provided to the investigative sites.  
TSH   
HbA1c       
    
Genetics Sample  Assayed by [CONTACT_11007] -designated laboratory.  
Results will not be provided to the investigative 
sites.  
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
62 Clinical Laboratory Tests   Comments  
Whole blood (EDTA)    
Exploratory Biomarker Storage Samples  Assayed by [CONTACT_11007] -designated laboratory.  
Results will not be provided to the investigative 
sites.  
  Serum    
  Plasma (EDTA)    
Abbreviations: ADA = anti -drug antibodies;  ALP = alkaline phosphatase ; ALT = alanine aminotransferase ; 
ApoB  = apolipoprotein b ; AST = aspartate aminotransferase ; BUN = blood urea nitrogen ; CK = creatine kinase ; 
CKD -EPI = chronic kidney disease epi[INVESTIGATOR_8261] ; DNA = deoxyribonucleic acid ; 
EDTA  = ethylenediamine tetraacetic acid ; eGFR = estimated glomerular filtration rate; FSH = f ollicle -
stimulating hormone ; GGT = g amma -glutamyl transferase ; HbA1c = hemoglobin A1c ; HbcAb = hepatitis B core 
antibody; H bsAb = hepatitis B surface antibody; H bsAg = hepatitis B surface antigen; HBV = hepatitis B virus; 
HCV = hepatitis C vir us; HDL -C = high -density lipoprotein -cholesterol ; HIV = human immunodeficiency virus; 
hsCRP = h igh-sensitivity C -reactive protein ; LDL -C = l ow-density lipoprotein -cholesterol ; 
Lp(a)  = Lipoprotein(a) ; RBC = red blood cell; RNA = ribonucleic acid ; TSH = thyroid stimulating hormone ; 
UACR = urine albumin creatinine ratio ; VLDL -C = v ery low-density lipoprotein ; WBC = white blood cell.  
10.2.1.  Laboratory Samples to be Obtained at the Time of a Systemic Hypersensitivity 
Event  
Purpose of collecting samples after a systemic hypersensitivity event  
The samples listed in this appendix are not collected for acute study participant management. 
The sponsor will use the laboratory test results from these samples to characterize 
hypersen sitivity events across the clinical development program.  
When to collect samples after a systemic hypersensitivity event occurs  
Collect the samples listed below if a systemic hypersensitivity event is suspected. The timing 
should be as designated in the ta ble, assuming the participant has been stabilized.  
Obtain follow -up predose samples at the next regularly scheduled laboratory sample collection , 
ideally prior to the next dose after the event , to assess post -event return -to-baseline values.  
Approved on [ADDRESS_199272] from 30 minutes to 4 hours 
after the start of the event.  
● Note: The optimal 
collection time is from 1 to 
2 hours after the start of event.  Serum  total tryptase  
Serum  complements ( C3, C3a, and C5a)  
Serum  cytokine panel ( IL-6, IL‐1β, IL‐10 or any cytokine 
panel that includes these 3 cytokines)  
Collect only if not already collected 
on the same day as the event.  
● Note: If collecting, collect 
up to 12 hours after the start of 
the event.  Serum  LY3819469 ADA  
Serum/plasma  LY3819469 concentration  
Abbreviations: ADA = anti -drug antibodies; IL = interleukin.  
a Sample type may be different depending on local requirements.  
b All samples for hypersensitivity testing will be assayed by [CONTACT_11007] -designated laboratory. Results will not be 
provided to the study site. If samples are not collected or are collected outside the specified time period, this will 
not be considered a protocol deviation.  
 
What information to record  
Record the date and time when the samples are collected.  
Allowed additional testing for participant management  
The investigator may perform additional tests locally, if clinically indicated, for acute study 
participant management.  
  
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
64 10.3. Appendix 3: Adverse Events  and Serious Adverse Events : Definitions 
and Procedures for Recording, Evaluating, Follow -up, and 
Reporting  
10.3.1.  Definition of AE  
AE Definition  
 An AE is any untoward medical occurrence in a participant administered a 
pharmaceutical product and  which does not necessarily have a causal relationship with 
the study intervention. An AE can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding), symptom, or disease (new or exacerbated) 
temporally associated with t he use of a medicinal (investigational) product, whether or 
not related to the medicinal (investigational) product.  
Events Meeting  the AE Definition  
 Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
other safety asse ssments ( for ex ample , ECG, radiological scans, vital signs 
measurements), including those that worsen from baseline, considered clinically 
significant in the medical and scientific judgment of the investigator ( that is , not related 
to progression of underl ying disease).  
 Exacerbation of a chronic or intermittent preexisting condition including either an 
increase in frequency and/or intensity of the condition.  
 New condition detected or diagnosed after study intervention administration even 
though it may have been present before the start of the study.  
 Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.  
 Medication error, misuse, or abuse of investigational medicinal product , including 
signs, symptoms, or clinical sequelae.   
 Lack of efficacy or failure of expected pharmacological action per se will not be 
reported as an AE or SAE. Such instances will be captured in the efficacy assessments. 
However, the signs, symptoms, and/or clinical sequelae resulting from lack of efficacy 
will be reported as AE or SAE if they fulfil l the definition o f an AE or SAE.   
Events NOT  Meeting the AE Definition  
 Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments that are associated with the underlying disea se, unless judged by [CONTACT_11009]’s condition.  
 The disease/disorder being studied or expected progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected fo r the participant’s 
condition.  
 Medical or surgical procedure ( for example , endoscopy, appendectomy): the condition 
that leads to the procedure is the AE.  
 Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).  
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
65  Anticipated day -to-day fluctuations of preexisting  disease(s) or condition(s) present or 
detected at the start of the study that do not worsen.   
10.3.2.  Definition of SAE  
An SAE is defined as any untoward medical occurrence that, at any dose , meets one or 
more of the criteria listed : 
a. Results in death  
b. Is life -threatening  
The term life-threatening  in the definition of serious  refers to an event in which the participant 
was at risk of death at the time of the event. It does not refer to an event, which hypothetically 
might have caused death, if it were more severe.  
c. Requires inpatient hospi[INVESTIGATOR_10909]  
 In general, hospi[INVESTIGATOR_51955] (usually involving at least an overnight stay) for observation and/or 
treatment that would not have been appropriate in the physicia n’s office or outpatient 
setting. Complications that occur during hospi[INVESTIGATOR_1084]. If a complication 
prolongs hospi[INVESTIGATOR_9236], the event is serious. When 
in doubt as to whether hospi[INVESTIGATOR_51956], the AE should be 
considered serious.  
 Hospi[INVESTIGATOR_5187] a preexisting condition that did not worsen 
from baseline is not considered an AE.  
d. Results in persistent disability/incapacity  
 The term disability means a substantia l disruption of a person’s ability to conduct 
normal life functions.  
 This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental traum a (for example , sprained ankle) which may interfere with or 
prevent everyday life functions but do not constitute a substantial disruption.  
e. Is a congenital anomaly/birth defect  
 Abnormal pregnancy outcomes ( for example , spontaneous abortion, fetal death, 
stillbirth, congenital anomalies, ectopic pregnancy) are considered SAEs.  
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
66 f. Other situations:  
 Medical or scientific judgment should be exercised by [CONTACT_170280] -threatening or result in death or hospi[INVESTIGATOR_51957]. These events should 
usually be considered serious.  
 Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059] , or development of drug dependency or 
drug abuse.   
10.3.3.  Definition of Product Complaints  
Product Complaint  
 A product complaint is any written, electronic, or oral communication that alleges 
deficiencies related to the identity, quality, durability,  reliability, safety, effectiveness , 
or performance of a study  intervention . When the ability to use the study intervention 
safely is impacted, the following are also product complaints:  
o Deficiencies in labeling information, and  
o Use errors for device or drug-device combination products due to ergonomic 
design elements of the product.  
 Product complaints related to study inte rventions used in clinical trials are collected in 
order to ensure the safety of participants, monitor quality, and to facilitate proces s and 
product improvements.  
 Investigators will instruct p articipants to contact [CONTACT_11010] a product complaint or problem with the study inte rvention  so that the situation can 
be assessed.  
 An event may meet the definition  of both a product complaint and an AE/SAE. In such 
cases, it should be reported as both a product complaint and as an AE/SAE.  
10.3.4.  Recording and Follow -Up of AE and/or SAE  and Product Complaints  
AE, SAE , and Product Complaint  Recording  
 When an AE/SAE /product complaint  occurs, it is the responsibility of the investigator 
to review all documentation ( for example , hospi[INVESTIGATOR_1088], laboratory reports, 
and diagnostics reports) related to the event.  
 The investigator will then record all releva nt AE/ SAE /product complaint  information 
in the participant’s medical records, in accordance with the investigator’s normal 
clinical practice . AE/SAE information is reported o n the appropriate  CRF  page and 
product complaint  information is reported on the Pr oduct Complaint Form . 
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
67 Note: An event may meet the definition of both a product complaint and an AE/SAE. 
In such cases, it should be reported as both a product complaint  and as an AE/SAE.  
 It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s medical 
records to sponsor or designee  in lieu of completion of the CRF page  for AE/SAE and 
the Product Complaint Form for product complaints . 
 There may be instances when copi[INVESTIGATOR_1309] m edical records for certain cases are requested 
by [CONTACT_170281] . In this case, all participant identifiers, with the exception of the 
participant number, will be redacted on the copi[INVESTIGATOR_170249] . 
 The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE .  
Assessment of Intensity  
The investigator will make an assessment of intensity for each AE and SAE reported during 
the study and assign it to one of the following categories:   
 Mild:  A type of AE that is usually transient and may require only minimal treatment or 
therapeutic intervention. The event does not generally interfere with usual activities of 
daily living . 
 Moderate:  A type of AE that is usually alleviated with additional specific therapeu tic 
intervention. The event interferes with usual activities of daily living, causing 
discomfort but poses no significant or permanent risk of harm to the research 
participant . 
 Severe: A type of AE that interrupts usual activities of daily living, or signi ficantly 
affects clinical status, or may require intensive therapeutic intervention . An AE that is 
assessed as severe should not be confused with an SAE. Severe is a category utilized 
for rating the intensity of an event; and both AEs and SAEs can be asses sed as severe.  
An event is defined as “serious”  when it meets at least one of the predefined outcomes 
as described in the definition of an SAE, NOT when it is rated as severe.   
Assessment of Causality  
 The investigator is obligated to assess the relationship between study intervention and 
each occurrence of each AE/SAE.  The investigator will use clinical judgment to 
determine the relationship . 
 A “reasonable possibility ” of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot be 
ruled out.  
 Alternative causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as  well as the temporal relationship of the event to study intervention 
administration will be considered and investigated.  
 The investigator will also consult the IB in their assessment.  
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
68  For each AE/SAE, the investigator must  document in the medical notes th at he/she has 
reviewed the AE/SAE and has provided an assessment of causality.  
 There may be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to sponsor or designee . However, it 
is very im portant that the investigator always make an assessment of causality for 
every event before the initial transmission of the SAE data to sponsor or designee . 
 The investigator may change their opi[INVESTIGATOR_9242] -up 
information and send an SAE follow -up report with the updated causality assessment.  
 The causality assessment is one of the criteria used when determining regulatory 
reporting requirements.  
Follow -up of AEs and SAEs  
 The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [CONTACT_11011]/or causality of the AE or SAE as fully as possible . 
This may include additional laboratory tests or investigations, histopathological 
examinations, or consultation with other health care professionals.  
10.3.5.  Reporting of SAEs  
SAE Reporting via an Electronic Data Collection Tool  
 The primary mechanism  for reporting an SAE will be the electronic data collection 
tool. 
 If the electronic system is unavailable, then the site will use the SAE paper form (see 
next section) in order to report the event within 24 hours.   
 The site will enter the SAE data into th e electronic system as soon as it becomes 
available.  
 After the study is completed at a given site, the electronic data collection tool will be 
taken off -line to prevent the entry of new data or changes to existing data.  
 If a site receives a report of a new  SAE from a study participant or receives updated 
data on a previously reported SAE after the electronic data collection tool has been 
taken off -line, then the site can report this information on an SAE paper form (see next 
section) or to the medical monit or/SAE coordinator  by [CONTACT_756].  
 Contacts for SAE reporting can be found in the SAE paper form. 
SAE Reporting via Paper Form  
 Facsimile transmission of the SAE paper form  is the preferred method to transmit this 
information to the medical monitor or the SAE coordinator . 
 Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.  
 Contacts for SAE reporting can be found in  the SAE paper form.  
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
69 10.3.6.  Regulato ry Reporting Requirements  
SAE Regulatory Reporting  
● Prompt notification by [CONTACT_11012] a n SAE is essential so 
that legal obligations and ethical responsibilities towards the safety of 
participants and the safety of a study intervention under clinical investigation 
are met.  
● The sponsor has a legal responsibility to notify both the local regulatory 
authority and other regulatory agencies about the safety of a study intervention 
under clinical investigation. The sponsor will comply with country -specific 
regulatory requirements relating to safety reporting to the regulatory authority, 
IRB/IEC , and investigators.  
● An investigator who receives an investigator safety report describing a n SAE or 
other specific safety information ( for example , summary or listing of SAEs) 
from the spo nsor will review and then file it along with the IB and will notify 
the IRB/IEC, if appropriate according to local requirements.   
  
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
70 10.4. Appendix 4: Contraceptive and Barrier Guidance  
10.4.1.  Definitions  
Word/Phrase  Definition  
Women of childbearing 
potential ( WOCBP)  Adult females are considered WOCBP unless they are WNOCBP . 
 
Women not of 
childbearing potential  
(WNOCBP)  Females are considered WNOCBP  if they  
 have a congenital anomaly such as Müllerian agenesis  
 are infertile due to surgical sterilization, or  
 are postm enopausal.  
Examples of surgical sterilization include total hysterectomy, 
bilateral salpi[INVESTIGATOR_8936] -oophorectomy, bilateral salpi[INVESTIGATOR_1656], or 
bilateral oophorectomy.  
Postmenopausal state  The postmenopausal state is defined as a woman:  
 at any age at least 6 weeks postsurgical bilateral 
oophorectomy with or without hysterectomy, confirmed by 
[CONTACT_31083]; or  
 aged at least [ADDRESS_199273] 12 consecutive months without an 
alternative medical cause, AND with a follicle -stimulating 
hormone >40 mIU/mL; or  
 [ADDRESS_199274] 12 months of spontaneous amenorrhea, or  
 aged at least 55 years with a d iagnosis of menopause prior to 
starting hormone replacement therapy.  
 
Abbreviation: SERM = selective estrogen receptor modulator . 
a Women should not be taking medications during amenorrhea such as oral contraceptives, hormones, 
gonadotropin -releasing hormone, anti -estrogens, SERMs, or chemotherapy that could induce transient 
amenorrhea.  
 
10.4.2.  Contraception Guidance  
[IP_ADDRESS].  Female Participants  
Female participants of childbearing potential are excluded from the trial.  
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
71 [IP_ADDRESS].  Male Participants  
The table below describes contraception guidance for men.  
Topic  Guidance  
For all men  should refrain from sperm donation for the 
duration of the study  
Contraception for men with partners of 
childbearing potential   either remain abstinent (if this is their 
preferred and usual lifestyle), or  
 must use condoms during intercourse for 
the duration of the study  
Contraception for men in exclusively same sex 
relationships, as their preferred and usual lifestyle  Are not required to use contraception  
 
Examples of highly effective, effe ctive , and unacceptable methods of contraception can be found below.  
Methods  Examples  
Highly effective contraception   combination oral contraceptive pi[INVESTIGATOR_31076]-pi[INVESTIGATOR_4382] 
 implanted contraceptives  
 injectable contraceptives  
 contraceptive patch (only women 
<198  pounds or 90 kg)  
 total abstinence  
 vasectomy (if only sexual partner)  
 fallopi[INVESTIGATOR_31077] (if confirmed by 
[CONTACT_31084][INVESTIGATOR_8913])  
 combined contraceptive vaginal ring, or  
 intrauterine devices  
Effective contraception   male or female condoms with spermici de  
 diaphragms with spermicide or cervical 
sponges  
 barrier method with use of a spermicide  
o condom with spermicide  
o  diaphragm with spermicide, or  
o female condom with spermicide  
 
Note: The barrier method must include use of a 
spermicide (i.e., condom with spermicide, 
diaphragm with spermicide, female condom with 
spermicide) to be considered effective.  
Ineffective forms of contraception   spermicide alone  
 immunocontraceptives  
 periodic abstinence  
 fertility awareness (calendar method, 
temperature method, combi nation of 
above 2, cervical mucus, symptothermal)  
 withdrawal,  
 post coital douche  
 lactational amenorrhea  
  
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
72 10.5. Appendix  5: Genetics  
Use/Analysis of DNA  
● Genetic variation may impact a participant’s response to study intervention, 
susceptibility to, and severity and progression of disease. Variable response to 
study intervention may be due to genetic determinants that impact drug 
absorption, distribution, metabolis m, and excretion; mechanism of action of the 
drug; disease etiology; and/or molecular subtype of the disease being treated. 
Therefore, where local regulations and IRB/IEC allow, an optional blood sample 
will be collected for DNA analysis from consenting pa rticipants.  
● DNA samples will be used for research related to study intervention  or 
cardiovascular disease and related diseases. They may also be used to develop 
tests or assays including diagnostic tests related to study intervention and 
cardiovascular d isease. Genetic research may consist of the analysis of 1 or more 
candidate genes or the analysis of genetic markers throughout the genome or 
analysis of the entire genome  (as appropriate).  
● The samples may be analyzed as part of a multi -study assessment of genetic 
factors involved in the response to study intervention  or study interventions of this 
class to understand study disease or related conditions.  
● The results of genetic analyses may be reported in the CSR or in a separate study 
summary.  
● The spo nsor will store the DNA samples in a secure storage space with adequate 
measures to protect confidentiality.  
● The samples will be retained while research on study intervention continues but 
no longer than 7 years or other period as per local requirements.  
  
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
73 10.6. Appendix 6: Liver Safety: Suggested Actions and Follow -up 
Assessments  
Hepatic Evaluation Testing  
See Section 8.2.[ADDRESS_199275] be qualified in accordance with applicable local regulations.  
Tests assayed by [CONTACT_11007] -designated central laboratory  
Hepatic Hematology Panel  Hepatitis A virus (HAV) testing:  
   Hemoglobin      HAV total antibody  
   Hematocrit      HAV IgM antibody  
   Erythrocytes (RBCs – red blood cells)  Hepatis B virus (HBV) testing:  
   Leukocytes (WBCs – white blood cells)      Hepatitis B surface antigen (H bsAg)  
   Differential:      Hepatitis B surface antibody (anti -HBs)  
       Neutrophils, segmented      Hepatitis B core total antib ody (anti -HBc)  
       Lymphocytes      Hepatitis B core IgM antibody  
       Monocytes      HBV DNA  b 
       Basophils  Hepatis C virus (HCV) testing:  
       Eosinophils      HCV antibody  
   Platelets      HCV RNA b 
   Cell morphology (RBC and WBC)  Hepatitis D virus (HDV) testing:  
Hepatic Clinical Chemistry Panel      HDV antibody  
   Total bilirubin  Hepatitis E virus (HEV) testing:  
   Direct bilirubin      HEV IgG antibody  
   Alkaline phosphatase (ALP)      HEV IgM antibody  
   Alanine aminotransferase (ALT)      HEV RNA b 
   Aspartate aminotransferase (AST)  Anti -nuclear antibody (ANA)  
   Gamma -glutamyl transferase (GGT)  Anti -smooth muscle antibody (ASMA) a 
   Creatine kinase (CK)  Anti -actin antibody c 
Hepatic Coagulation Panel  Immunoglobulin IgA (quantitative)  
   Prothrombin time, INR (PT -INR)  Immunoglobulin IgG (quantitative) 
Urine Chemistry  Immunoglobulin IgM (quantitative)  
   Drug screen  Epstein -Barr virus (EBV) testing:  
Haptoglobin      EBV antibody  
Tests assayed ONLY by [CONTACT_1697] -designated local laboratory  
Acetaminophen  Cytomegalovirus (CMV) testing:  
Acetaminophen protein adducts      CMV antibody  
Alkaline phosphatase isoenzymes      CMV DNA  b 
Ceruloplasmin  Herpes simplex virus (HSV) testing:  
Copper      HSV (Type 1 and 2) antibody  
Ethyl alcohol (EtOH)      HSV (Type 1 and 2) DNA  b 
Phosphatidylethanol (P eth) Liver kidney microsomal type 1 (LKM -1) antibody  
Urine Chemistry  Microbiology  
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
74 Tests assayed ONLY by [CONTACT_1697] -designated local laboratory  
    Ethyl glucuronide (EtG)  Culture:  
Epstein -Barr virus (EBV) testing:      Blood  
    EBV DNA b     Urine  
a Not required if anti -actin antibody is tested.  
b Reflex/confirmation dependent on regulatory requirements, testing availability, or both.  
c Not required if anti -smooth muscle antibody (ASMA) is tested.  
 
  
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
75 10.7. Appendix 7: Provisions for Changes in Study Conduct During 
Exceptional Circumstances  
Implementation of this appendix  
The changes to procedures described in this appendix are temporary measures intended to be used only 
during specific time periods as direct ed by [CONTACT_170282].  
Exceptional circumstances  
Exceptional circumstances are rare events  that may cause disruptions to the conduct of the study. 
Examples include pandemics or natural disasters. These disruptions may limit the ability of the 
investigators, participants, or both to attend on -site visits or to conduct planned study procedures.  
Implementing changes under exceptional circumstances  
In an exceptional circumstance, after receiving the sponsor’s written approval, sites may implement 
changes if permitted by [CONTACT_427].  
After approval by [CONTACT_31086], regulatory bod ies, and  any other relevant local 
authorities, implementation of these exceptional circumstance changes will not typi[INVESTIGATOR_51960], unless they have specific requirements in which notification is 
required , for exampl e, upon implementation and suspension of changes. All approvals and notifications 
must be retained in the study records.  
If the sponsor grants written approval for changes in study conduct, the sponsor will also provide 
additional written guidance, if need ed. 
Considerations for making a change  
The prevailing consideration for making a change is ensuring the safety of study participants. Additional 
important considerations for making a change are compliance with GCP , enabling participants to continue 
safely in the study , and maintaining the integrity of the study.  
Informed consent  
Additional consent from the participant will be obtained, if required, for  
 participation in remote visits, as defined in Section “Remote Visits”  
 dispensation of additional study int ervention during an extended treatment period  
 alternate delivery of study intervention and ancillary supplies, and  
 provision of their personal or medical information required prior to implementation of these 
activities.  
 
Changes in study conduct during exceptional circumstances  
Changes in study conduct not described in this appendix, or not consistent with applicable local 
regulations, are not allowed.  
The following changes in study conduct will not be considered protocol deviations.  
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
76 Remote visits  
Types of remote visits  
Telemedicine:  Telephone or technology -assisted virtual visits, or both, are acceptable to 
complete appropriate assessments. Assessments to be completed in this manner include, but are 
not limited to  
 AE review  
 concomitant medication review  
 substance use (alcohol) , and  
 PCs (if applicable).  
Mobile healthcare:  Healthcare visits may be performed by a mobile healthcare provider at 
locations other than the study site when participants cannot travel to the site due to an exceptional 
circumstance if  written approval is provided by [CONTACT_456] . Procedures performed at such visits 
include, but are not limited to  
 concomitant medications  
 collection of blood samples  
 physical assessments, and  
 health information.  
Other alternative locations:  A local laborat ory may be used for laboratory draws.  
Assessments that may need to be delayed until the next on -site visit or missed, depending on the 
length of time that sites or participants are impacted and depending on when on -site visits are 
due, include  
 vital signs  
 weight  
 symptom -directed physical examination, and  
 laboratory tests if a local laboratory cannot be used.  
Data capture  
In source documents and the CRF, the study site should capture the visit method, with a specific 
explanation for any data missing because of missed in -person site visits.  
Safety reporting  
Regardless of the type of remote visits implemented, the protocol requirements regarding the reporting of 
AEs, SAEs, and PCs remain unchanged.  
Return to on -site visits  
Every effort should be made to enable participants to return to on -site visits as soon as reasonably 
possible, while ensuring the safety of both the participants and the site staff.  
Approved on [ADDRESS_199276] be retained for PK, Lp(a), ApoB, hsCRP, and the lipid panel.  
Study intervention and ancillary supplies (including par ticipant diaries)  
When a  participant is unable to go to the site to receive study supplies during normal on -site visits, the 
site should work with the sponsor to determine appropriate actions. These actions may include  
 asking the participant to go to the s ite and receive study supplies from site staff without 
completion of a full study visit  
 asking the participant’s designee to go to the site and receive study supplies on a participant’s 
behalf  
 arranging delivery of study supplies , and  
 working with the spon sor to determine how study intervention that is typi[INVESTIGATOR_170250]; for example, during a mobile healthcare visit 
or at an alternate location such as an infusion center.  
 
These requirements must be met be fore action is taken : 
 Alternate delivery of study intervention should be performed in a manner that does not 
compromise treatment blinding and ensures product integrity. The existing protocol 
requirements for product accountability remain unchanged, includ ing verification of 
participant’s receipt of study supplies.  
 When delivering supplies to a location other than the study site (for example, participant’s 
home), the investigator, sponsor, or both should ensure oversight of the shippi[INVESTIGATOR_170251] , that is, storage conditions maintained and intact 
packaging upon receipt.  
 Instructions may be provided to the participant or designee on the final disposition of any 
unused or completed study supplies . 
If study interventio n will be administered to the participant during a mobile healthcare visit or at an 
alternate location, these additional requirements must be met:  
 Only authorized study personnel may supply, prepare , or administer study intervention.  
 Follow all other requirements that are consistent with the main protocol.  
 
Screening period guidance  
To ensure safety of study participants, laboratory values , and other eligibility assessments taken at 
prescreening and screening visits  are valid for a maximum of [ADDRESS_199277] be paused due to exceptional 
circumstances:  
 If screening is paused for less than 60 days from signing the ICF to randomization visit : the 
participant will proceed to the next study visit per the usual SoA, provided that randomization 
visit must be conducted within [ADDRESS_199278] the next visit if the participant’s eligibility criteria are 
confirmed, and the site should document the reason for delay.  
o Due to the pause in screening, sites should also reconfirm the impacted participant’s 
consent and document this confirmation in the source documentation.  
 If screening is paused for more than 60 days from screening visits to randomization visit:  the 
participant must be discontinued because of screening interruption due to an exceptional 
circumstance.  This is documented as a screen failure in the CRF.  The participant can 
reconsent and be rescreened as a new participant. This rescreen is in addition to the one 
allowed by [CONTACT_141730].  The screening procedures per the usual SoA should be 
followed, starting at screening visit to ensure participant eligibility by [CONTACT_170283].  
 
Adjustments to vi sit windows  
Whenever possible and safe to do so, as determined by [CONTACT_093]’s discretion, participants should 
complete the usual SoA. To maximize the possibility that these visits can be conducted as on -site visits, 
the windows for visits may be adj usted, upon further guidance from the sponsor. This minimizes missing 
data and preserves the intended conduct of the study.  
Documentation  
Changes to study conduct will be documented  
Sites will identify and document the details of how participants, visits type, and conducted activities were 
affected by [CONTACT_52022]. Dispensing  or shipment records of study intervention and relevant 
communications, including delegation, should be filed with site study records.  
Source documents at alternate locati ons 
Source documents generated at a location other than the study site should be part of the 
investigator’s  source documentation and should be transferred to the site in a secure and timely manner.  
 
 
  
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
79 10.8. Appendix 8: Abbreviations  and Definitions  
Term  Definition  
AC assessment committee  
ACC  American College of Cardiology  
ADA  anti-drug antibodies  
AE adverse event  
AHA  American Heart Association  
ALP alkaline phosphatase  
ALT alanine aminotransferase  
ANCOVA  analysis of covariance  
Apo(a) apolipoprotein(a)  
ApoB  apolipoprotein B  
ASCVD  atherosclerotic cardiovascular disease  
AST aspartate aminotransferase  
AUC  area under the curve  
blinding/masking  A double -blind study is one in which neither the participant nor any of the investigator s or 
sponsor staff who are involved in the treatment or clinical evaluation of the subjects are 
aware of the treatment received.  
CAD  coronary artery disease  
CFR Code of Federal Regulations  
CIOMS  Council for International Organizations of Medical Sciences  
CK creatine kinase  
CKD -EPI [INVESTIGATOR_170252] (assay or test) that provides information that is essential for 
the safe and effective use of a corresponding therapeutic product . 
Complaint  A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or dr ug delivery system.  
Compliance  Adherence to all study -related, good clinical practice (GCP), and applicable regulatory 
requirements.  
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
80 CONSORT  Consolidated Standards of Reporting Trials  
CRF case report form; a printed, optical, or electronic document desi gned to record all of the 
protocol -required information to be reported to the sponsor for each trial participant.  
CSR  clinical study report  
CT computerized tomography  
CTA Clinical Trial Agreement  
D. Bil  direct bilirubi n 
DNA  deoxyribonucleic acid  
EBV Epstein -Barr virus  
ECG  electrocardiogram  
ED early discontinuation  
EDC  electronic data capture system  
eGFR  estimated glomerular filtration rate  
Enroll  The act of assigning a participant to a treatment. Participants who are enrolled in the study 
are those who have been assigned to a treatment.  
Enter Participants entered into a study are those who sign the informed consent form directly or 
through their legally acceptable representatives.  
ERCP  endoscopic retrograde cholangiopancreatography  
EU European Union  
FAS Full Analysis Set  
GCP  good clinical practice  
GGT  gamma -glutamyltransferase  
HbA1c  hemoglobin A1c  
HBV  hepatitis B virus  
HbcAb hepatitis B core antibody  
HbsAg hepatitis B surface antigen  
HCV  hepatitis C virus  
HDV  hepatitis D virus  
HIV human immunodeficiency virus  
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
81 hsCRP  high-sensitivity C -reactive protein  
IB Investigator’s Brochure  
ICF informed consent form  
ICH International Council for Harmonisation  
IEC Independent Ethics Committees  
Informed consent  A process by [CONTACT_9444] a participant voluntarily confirms their willingness to participate in a 
particular study, after having been informed of all aspects of the study that are relevant to 
the participant’s decision to participate. Informed consent is documented by [CONTACT_3553] a 
written, signed, and dated informed consent form . 
Interim analysis  An interim analysis is an analysis of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is created or locked.  
INR international norm alized ratio  
investigational 
product  A pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial, including products already on the market when used or 
assembled (formulated or packaged) in a way differ ent from the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to gain 
further information about the authorized form.  
IRB Institutional Review Board  
ISR injection site reaction  
IWRS  interactive web-response system  
Lp(a)  lipoprotein(a)  
MACE  major adverse cardiac events  
MedDRA  Medical Dictionary for Regulatory Activities  
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
82 medication error  Errors in the prescribing, dispensing, or administration of a study intervention, 
regardless of whether or n ot the medication is administered to the participant or the 
error leads to an AE. Medication error s generally involve a failure to uphold one or 
more of the five “rights” of medication use: the right participant, the right drug, the 
right dose, right route , at the right time.  
In addition to the core five rights, the following may also represent medication errors:  
• dose omission associated with an AE or a product complaint  
• dispensing or use of expi[INVESTIGATOR_51963]  
• use of medication past the recommended in-use date  
• dispensing or use of an improperly stored medication  
• use of an adulterated dosage form or administration technique inconsistent with the 
medication ’s labeling (for example, Summary of Product Characteristics, IB, local 
label, protocol), or  
• shared use of cartridges, prefilled pens, or both.  
Misuse  Use of a study intervention for self -treatment that either is inconsistent with the 
prescribed dosing regimen, indication, or both, or is obtained without a prescription  
MMRM  mixed model for rep eated measures  
MRCP  magnetic resonance cholangiopancreatography  
OTC  over the counter  
participant  equivalent to CDISC term “subject”: an individual who participates in a clinical trial, either 
as recipi[INVESTIGATOR_10930] a control  
PC product complaint  
PCR  polymerase chain reaction  
PCSK9  proprotein convertase subtilisin/kexin type 9  
PD pharmacodynamics  
PK pharmacokinetics  
PT-INR prothrombin time -INR 
QTc corrected QT interval  
QTcF  QT interval corrected using Fridericia’s formula  
QTL quality tolerance limit  
RNA  ribonucleic acid  
SAE serious adverse event  
SAP statistical analysis plan  
Approved on [ADDRESS_199279] of determining if an individual meets minimum requirements to become part of a 
pool of potential candidates for participation in a clinical study.  
siRNA  small interfering  ribonucleic acid  
SNP single -nucleotide polymorphism  
SoA Schedule of Activ ities 
TBL total bilirubin  
TE-ADA  treatment -emergent anti -drug antibodies  
TEAE  Treatment -emergent adverse event: An untoward medical occurrence that emerges during a 
defined treatment period, having been absent pretreatment, or worsens relative to the 
pretreatment state, and does not necessarily have to have a causal relationship with this 
treatment.  
ULN upper limit of normal  
WNOCBP  women not of childbearing potential  
WOCBP  women of childbearing potential  
 
  
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
84 11. References  
AIM -HIGH Investigators. The role of niacin in raising high -density lipoprotein cholesterol to 
reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and 
optimally treated low -density lipoprotein cholesterol Rationale and study  design. The 
Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: 
Impact on Global Health outcomes (AIM -HIGH). Am Heart J . 2011;161(3):471 -477.e2. doi: 
10.1016/j.ahj.2010.11.017  
Clarke R, Peden JF, Hopewell JC, et al. ; PROCA RDIS Consortium. Genetic variants associated 
with Lp(a) lipoprotein level and coronary disease. N Engl J Med . 2009;361(26):2518 -2528. 
doi: 10.1056/NEJMoa0902604  
Dubé JB, Boffa MB, Hegele RA, Koschinsky ML. Lipoprotein(a): more interesting than ever 
AIM -HIGH Investigators. The role of niacin in raising high -density lipoprotein after 50 years. 
Curr Opin Lipi[INVESTIGATOR_37487] . 2012;23(2):133 -140. doi: 10.1097/MOL.0b013e32835111d8  
Emdin CA, Khera AV, Natarajan P, et al. ; CHARGE –Heart Failure Consortium; 
CARDIoGRAM Exome Cons ortium. Phenotypic Characterization of Genetically Lowered 
Human Lipoprotein(a) Levels. J Am Coll Cardiol . 2016;68(25):2761 -2772. doi: 
10.1016/j.jacc.2016.10.[ADDRESS_199280], et al. Lipoprotein(a) 
conce ntration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA . 
2009;302(4):412 -423. doi: 10.1001/jama.2009.1063  
Ference BA. The potential clinical benefit of lowering lipoprotein (a). JAMA . 
2022;327(17):1653 -1655. doi: 10.1001/jama.2022.5333   
Grundy SM, Stone NJ, Bailey AL, et al. 2018 
AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline 
on the Management of Blood Cholesterol: A Report of the American College of 
Cardiology/American Heart Association Task For ce on Clinical Practice Guidelines. 
Circulation . 2019;139(25):e1082 -e1143. doi: 10.1161/CIR.0000000000000625  
Erratum in: Circulation . 2019;139(25):e1182 -e1186.  
HPS2 -THRIVE Collaborative Group ; Landray  MJ, Haynes  R, Hopewell  JC, et al. Effects of 
extended -release niacin with laropi[INVESTIGATOR_170253] -risk patients. NEJM . 2014;371:203 -212. doi: 
10.1056/NEJMoa1300955  
Jaeger BR, Richter Y, Nagel D, et al. ; Group of Clinical Investigators. Longitudinal cohort study 
on the effectiveness of lipid apheresis treatment to  reduce high lipoprotein(a) levels and 
prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med . 2009;6(3):229 -239. 
doi: 10.1038/ncpcardio1456  
Kamstrup PR, Tybjaerg -Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated 
lipoprotein(a) and increased risk of myocardial infarction. JAMA . 2009;301(22):2331 -2339. 
doi: 10.1001/jama.2009.801  
Koren MJ, Moriarty PM, Baum SJ, et al. Preclinical deve lopment and phase 1 trial of a novel 
siRNA targeting lipoprotein(a). Nat Med . 2022;28(1):96 -103. doi:10.1038/s41591 -021-[ZIP_CODE] -
w 
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
85 Kronenberg F, Utermann G. Lipoprotein(a): resurrected by [INVESTIGATOR_7009]. J Intern Med . 
2013;273(1):6 -30. doi: 10.1111/j.1365 -2796.2012 .[ZIP_CODE].x  
Li Y, Luke MM, Shiffman D, Devlin JJ. Genetic variants in the apolipoprotein(a) gene and 
coronary heart disease. Circ Cardiovasc Genet . 2011;4(5):565 -573. 
doi:10.1161/CIRCGENETICS.111.959601  
Maeda S, Abe A, Seishima M, et al. Transient changes of serum lipoprotein(a) as an acute phase 
protein. Atherosclerosis . 1989;78(2 -3):145 -150. doi:10.1016/0021 -9150(89)[ZIP_CODE] -9 
Min WK, Lee JO, Huh JW. Relation between lipoprotein(a) concentrations in patients with 
acute -phase response and risk analysis for coron ary heart disease. Clin Chem . 
1997;43(10):1891 -1895.  
Nissen SE, Wolski K, Balog C, et al. Single ascending dose study of a short interfering RNA 
targeting lipoprotein (a) production in individuals with elevated plasma lipoprotein (a) levels . 
JAMA . 2022;327(17):1679 -1687. doi:10.1001/jama.2022.5050  
Noma A, Abe A, Maeda S, et al. Lp(a): an acute -phase reactant?. Chem Phys Lipi[INVESTIGATOR_805] . 1994;67 -
68:411 -417. doi:10.1016/0009 -3084(94)[ZIP_CODE] -3 
Nugent  AK, Gray  JV, Gorby  [CONTACT_170284], Moriarty  PM. Lipoprotein apheresis : first FDA indicated 
treatment for elevated lipoprotein (a). J Clin Cardiol . 2020;1:16 -21  
Robinson JG, Farnier M, Krempf M, et al. ; ODYSSEY LONG TERM Investigators. Efficacy 
and safety of alirocumab in reducing lipi[INVESTIGATOR_76603]. N Engl J Med . 
2015;372(16):1489 -1499. doi: 10.1056/NEJMoa1501031  
Sabatine MS, Giugliano RP, Wiviott SD, et al. ; Open -Label Study of Long -Term Evaluation 
against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in 
reducing lipi[INVESTIGATOR_76603]. N Engl J Med . 2015;372(16):1500 -1509. doi: 
10.1056/NEJMoa1500858  
Schmidt K, Noureen A,  Kronenberg F, Utermann G. Structure, function, and genetics of 
lipoprotein (a). J Lipid Res . 2016;57(8):1339 -1359. doi: 10.1194/jlr.R067314  
Stoekenbroek  R, Ray  K, Landmesser  U, et al.  4945  Inclisiran -mediated reductions in Lp(a) in the 
ORION -1 trial . Euro pean Heart Journal . 2019; 40(Supplement_1 ) 
https://doi.org/10.1093/eurheartj/ehz746.[ADDRESS_199281] in context : lipoprotein (a): diagnosis , prognosis , controversies , and emerging 
therapi[INVESTIGATOR_014] . J Am Coll Cardiol . 2017;69(6):692 -711. doi: 10.1016/j.jacc.2 016.11.042  
Tsimikas S, Stroes ESG. The dedicated "Lp(a) clinic": A concept whose time has arrived? 
Atherosclerosis . 2020;300:1 -9. doi: 10.1016/j.atherosclerosis.2020.03.003  
Tsimikas S, Karwatowska -Prokopczuk E, Gouni -Berthold I, et al. Lipoprotein(a) reduction in 
persons with cardiovascular disease . N Engl J Med . 2020;382(3):244 -255. 
doi:10.1056/NEJMoa1905239  
Utermann G. The mysteries of lipoprotein(a). Science . 1989;246(4932):904 -10. doi: 
10.1126/science.2530631  
Approved on 19 Jul 2022 GMT
CONFIDENTIAL  J3L-MC-EZEB  
 
86 Varvel S, McConnell JP, Tsimikas S. Prev alence of elevated Lp(a) mass levels and patient 
thresholds in 532 359 patients in the [LOCATION_002]. Arterioscler Thromb Vasc Biol . 
2016;36(11):2239 -2245. doi: 10.1161/ATVBAHA.116.308011  
Viney NJ, van Capelleveen JC, Geary RS, et al. Antisense oligonucleo tides targeting 
apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double -blind, placebo -
controlled, dose -ranging trials. Lancet . 2016;388([ZIP_CODE]):2239 -2253. doi: 10.1016/S0140 -
6736(16)[ZIP_CODE] -1 
 
Approved on 19 Jul 2022 GMT
Signature [CONTACT_11032]-CLIN-068490 v1.0
Signature [CONTACT_11032]-CLIN-068490 v1.0Approval
19-Jul-2022 13:09:15 GMT[PHONE_006]
Approval
19-Jul-2022 18:38:24 GMT[PHONE_006]
Approved on 19 Jul 2022 GMT
[COMPANY_003]
[COMPANY_003]